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Summary 
Eczema (atopic dermatitis) is one of the most common chronic inflammatory skin diseases in 
infants and children with prevalence rates of up to 20%. The disease frequently co-occurs with 
other atopic disorders such as asthma and rhinitis and is often accompanied by elevated 
levels of immunoglobulin E (IgE) antibodies and aberrant IgE-mediated responses to 
otherwise harmless environmental agents. 
Eczema is considered a polygenic disease, caused by a complex interplay of various 
predisposing genes, which additionally interact with environmental, non-genetic components. 
This work focuses on the identification of genetic factors contributing to the aetiology of 
eczema. To this end several candidate gene association studies were performed and the first 
and to date only genome-wide association studies (GWAS) on eczema as well as on total 
serum IgE levels were conducted. 
This thesis provides the first independent replication study on the filaggrin gene (FLG). FLG is 
located in the epidermal differentiation complex (EDC) on chromosome 1q21 and encodes a 
structural protein with key functions in the formation of the epidermal barrier. In a family-based 
approach it was clearly shown that the two loss-of-function mutations R501X and 2282del4 in 
this gene strongly predispose for eczema (Odds Ratio (OR) 2.73; P-value 5.1x10-8). Along with 
a consistent and prominent association between these mutations and eczema subsequent 
investigations delineated their impact on distinct eczema subtypes as well as on eczema-
related traits like asthma and hay fever. Strong associations with allergic sensitization (P 
2.3x10-7), increased total IgE (P 9.8x10-8) and the atopic (OR 3.66; P 4.6x10-5), but not the 
non-atopic form of eczema were observed. Both disease alleles predispose to the early-onset 
and severe form of eczema (OR 5.21 and 2.65; P 2.8x10-6 and 0.0043, respectively). It was 
demonstrated that mutant FLG alleles increase the risk for allergic rhinitis (OR 2.64; P 2.5x 
10-6), and patients with FLG-related eczema were shown to be at higher risk to develop 
additionally allergic asthma (OR 3.49; P 1.0x10-5). 
Moreover, it was possible to evaluate the relevance of FLG risk alleles on the population level 
in a German cross-sectional study. On the basis of an observed carrier frequency of 7.4% for 
the four most prevalent mutations the Population Attributable Risk (PAR) was estimated as 
high as 13.5% and the penetrance reached 38.5%. 
The remarkably strong effect of the FLG gene on eczema and asthma risk was finally 
confirmed with the help of a comprehensive meta-analysis based on 24 studies published until 
2008. This analysis emphasizes the important role of FLG as the first validated and strong 
genetic risk factor for eczema, and provides a general measure of its impressive effect size. 
FLG mutant alleles were shown to cause a more than threefold increased eczema risk and 
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clearly convey predisposition to the particular phenotype of asthma occurring in the context of 
eczema, but apparently not to asthma independent of eczema. 
These observations point towards a genetically disturbed epidermal barrier as key event in the 
pathogenesis of eczema and as risk factor for allergic sensitization and concomitant 
respiratory disease. 
The first GWA study on eczema published in 2009 identified a novel susceptibility locus on 
chromosome 11q (OR 1.22; P 7.64x10-10), as well as putative additional risk variants (OR 
1.20; P 3.52x10-5) apart from FLG within the EDC. The associated variant on chromosome 11 
is located in an intergenic region between the two plausible candidates C11orf30 
(chromosome 11 open reading frame 30) and LRRC32 (leucine rich repeat containing 32). 
Hence the gene affected by the identified risk allele on chromosome 11 is still elusive and 
subject of current investigations. 
With the help of an independent GWAS on total IgE levels it could be shown that variants 
within the gene encoding the alpha chain of the high affinity receptor for IgE (FCER1A) 
strongly influence serum IgE levels (P 7.08x10-19). Presence of the homozygous state of the 
rs2427837 minor allele was estimated to decrease serum IgE levels by 35%, and was strongly 
associated with decreased FCER1A cell surface expression on basophils. Concurrently, the 
study identified the cytokine cluster on chromosome 5q31 as a second susceptibility locus for 
altered IgE concentrations (P 6.28x10-7 - 4.46x10-8). 
Taken together, the discovery and comprehensive description of novel risk variants and 
potential susceptibility genes for eczema and related phenotypes change and complete our 
understanding of the complex aetiology of eczema and atopic diseases. Although to date 
immunological alterations have been the focus of pathophysiological considerations, new 
concepts recognize the impairment of the skin barrier as well as an abnormal reactivity of the 
adaptive and innate immune system as important factors. 
Eczema causes significant problems in everyday life and has been shown to lead to 
decreased quality of life, vitality, and mental health of patients, concurrently constituting a high 
economic burden with direct and indirect costs similar to those of asthma. Hence, the 
development of new prognostic and therapeutic tools is of essential relevance. Knowledge 
about the genetic background of eczema translates into a clearer understanding of 
mechanisms of the disease and ideally into the future development and refinement of 
diagnostic and therapeutic strategies. The challenge of future studies will be the further 
dissection of the genetic architecture of eczema and the confirmation of observed relations 
between variations in the human genome and eczema by functional approaches in order to 
illuminate the pathophysiological nature of this complex disease. 
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Zusammenfassung 
Das atopische Ekzem („Neurodermitis“, „atopische Dermatitis“) gilt mit einer Prävalenz von bis 
zu 20% als eine der häufigsten chronisch-entzündliche Hauterkrankung bei Säuglingen und 
Kindern. Die Krankheit tritt häufig in Kombination mit anderen atopischen Erkrankungen wie 
Asthma und Rhinitis auf und wird sehr oft von erhöhten Immunglobulin E (IgE) -Spiegeln im 
Serum und einer veränderten, IgE-vermittelten Immunantwort auf normalerweise harmlose 
Umweltagentien begleitet. 
Das atopische Ekzem wird als polygene Erkrankung verursacht durch ein komplexes 
Zusammenspiel mehrerer prädisponierender Gene betrachtet, die zusätzlich mit nicht-
genetischen Umweltkomponenten interagieren. 
Diese Arbeit befasst sich mit der Identifizierung genetischer Faktoren, die ursächlich an der 
Entstehung des atopischen Ekzems beteiligt sind. Zu diesem Zweck wurden mehrere 
Kandidatengen-Assoziationsstudien durchgeführt und es erfolgten die ersten und bislang 
einzigen genomweiten Assoziationsstudien (GWAS) zum atopischen Ekzem sowie zum 
Serum-IgE-Spiegel. 
Diese Doktorarbeit liefert die erste unabhängige Replikationsstudie zum Filaggrin-Gen (FLG). 
FLG ist im Epidermalen Differenzierungskomplex (EDC) auf Chromosom 1q21 lokalisiert und 
kodiert ein Strukturprotein mit Schlüsselfunktion bei der Entwicklung der epidermalen Barriere. 
In einer Familienstudie wurde klar gezeigt, dass die beiden Nullmutationen R501X und 
2282del4 in diesem Gen stark für das atopische Ekzem prädisponieren (Odds Ratio (OR) 
2.73; P-Wert 5.1x10-8). Zusammen mit einem konsistenten und prominenten Zusammenhang 
zwischen diesen Mutationen und dem atopischem Ekzem wurde deren Einfluss auf bestimmte 
Subphänotypen des atopischen Ekzems und verwandte Erkrankungen wie Asthma und 
Heuschnupfen in weiterführenden Versuchen erfolgreich dargestellt. Signifikante 
Assoziationen mit allergischer Sensibilisierung (P 2.3x10-7), erhöhtem IgE-Spiegel (P 9.8x10-8) 
und der extrinsischen (OR 3.66; P 4.6x10-5), nicht aber der intrinsischen Form des atopischen 
Ekzems wurden beobachtet. Beide Krankheitsallele prädisponieren zu frühem 
Krankheitsbeginn (<2 Jahre) und schwerer Ausprägung des Ekzems (OR 5.21 bzw. 2.65; P 
2.8x10-6 bzw. 0.0043). Es konnte nachgewiesen werden, dass die mutierten FLG Allele das 
Risiko für eine Erkrankung an allergischer Rhinitis erhöhen (OR 2.64; P 2.5x10-6) und 
Patienten mit FLG-bedingtem atopischen Ekzem außerdem ein höheres Risiko tragen, 
zusätzlich allergisches Asthma zu entwickeln (OR 3.49; P 1.0x10-5). 
Des Weiteren war es möglich, die Bedeutung der FLG Risikoallele auf Populationsebene in 
einer deutschen Querschnittsstudie aufzuzeigen. Auf Grundlage der beobachteten 
Trägerfrequenz von 7,4% für die vier häufigsten Mutationen lagen Schätzungen für das 
Populationsattributable Risiko (PAR) bei 13,5% und die Penetranz erreichte 38,5%. 
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Die außergewöhnliche Effektgröße dieses Gens in Bezug auf das Erkrankungsrisiko für 
atopisches Ekzem und Asthma wurde schließlich mit Hilfe einer umfassenden Metaanalyse, 
die auf 24 bis 2008 publizierten Studien basiert, bestätigt. Diese Analyse verdeutlicht die 
wichtige Rolle des FLG-Gens als erster validierter und starker genetischer Risikofaktor für das 
atopische Ekzem und liefert eine allgemein gültige Messung seiner beeindruckenden 
Effektgröße. Die mutierten FLG-Allele verursachen ein mehr als dreifach erhöhtes Risiko, an 
atopischem Ekzem zu erkranken, und sind für die deutliche Prädisposition zum spezifischen 
Phänotyp von Asthma im Kontext des atopischen Ekzems, nicht aber zu Asthma unabhängig 
vom atopischen Ekzem verantwortlich. 
Diese Beobachtungen deuten auf eine Schlüsselfunktion der genetisch bedingten Störung der 
epidermalen Barriere in der Pathogenese des atopischen Ekzems und auf ihre Bedeutung als 
Risikofaktor für allergische Sensibilisierung und begleitendes Asthma hin. 
Die erste GWAS zum atopischen Ekzem, die 2009 publiziert wurde, identifizierte einen neuen 
Suszeptibilitätslocus auf Chromosom 11q (OR 1.22; P 7.64x10-10), sowie mehrere zusätzliche 
und von FLG unabhängige potentielle Risikovarianten im EDC (OR 1.20; P 3.52x10-5). Das 
durch das identifizierte Risikoallel betroffene Gen auf Chromosom 11 ist noch unbekannt und 
Gegenstand gegenwärtiger Untersuchungen, da die assoziierte Variante in einer intergenen 
Region zwischen den beiden plausiblen Kandidaten C11orf30 (chromosome 11 open reading 
frame 30) und LRRC32 (leucine rich repeat containing 32) liegt. 
Mit Hilfe einer unabhängigen genomweiten Analyse zum Serum-IgE-Spiegel konnte gezeigt 
werden, dass Varianten im Gen der α-Kette des hochaffinen IgE-Rezeptors (FCER1A) die 
IgE-Konzentration stark beeinflussen (P 7.08x10-19). Schätzungen zeigten eine Senkung des 
IgE-Spiegels um 35% bei Vorhandensein des seltenen Allels von rs2427837 im homozygoten 
Zustand. Derselbe Genotyp war zusätzlich stark mit einer verringerten Expression von 
FCER1A auf der Oberfläche basophiler Granulozyten assoziiert. Gleichzeitig identifizierte die 
Studie das Zytokincluster auf Chromosom 5q31 als zweite Suszeptibilitätsregion für einen 
veränderten IgE-Spiegel (P 6.28x10-7 - 4.46x10-8). 
Die Entdeckung und Beschreibung neuer Risikovarianten und potentieller Suszeptibilitätsgene 
für das atopische Ekzem und verwandte Phänotypen verändert und erweitert unser 
Verständnis der komplexen Ätiologie des atopischen Ekzems und allergischer Erkrankungen. 
Nachdem bislang immunologische Veränderungen im Zentrum pathophysiologischer 
Überlegungen standen, sehen neuere Konzepte sowohl die funktionelle Einschränkung der 
Hautbarriere als auch eine veränderte Reaktionen des adaptiven und angeborenen 
Immunsystems als bedeutsam an. 
Das atopische Ekzem führt zu signifikanten Problemen im Alltag, und betroffene Individuen 
leiden unter einer einschneidenden Verminderung der Lebensqualität, Vitalität und 
psychischen Gesundheit. Gleichzeitig stellt die Erkrankung durch direkte und indirekte Kosten, 
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ähnlich wie Asthma, eine hohe ökonomische Belastung des Gesundheitssystems dar, so dass 
der Entwicklung neuer prognostischer und therapeutischer Ansätze große Bedeutung 
zukommt. Das Wissen um die genetischen Hintergründe des atopischen Ekzems führt zu 
einem besseren Verständnis der Krankheitsmechanismen und damit zur Entwicklung und 
Verbesserung diagnostischer und therapeutischer Strategien. Die Aufgabe zukünftiger Studien 
zur weiteren Aufklärung der pathophysiologischen Beschaffenheit dieser komplexen 
Erkrankung besteht in weiteren Analysen der genetischen Architektur des atopischen Ekzems 
und der Bestätigung der beobachteten Zusammenhänge zwischen Varianten im menschlichen 
Genom und der untersuchten Krankheit durch funktionelle Ansätze. 
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Abbreviations 
aa  amino acid 
AE  atopic eczema 
APC  antigen presenting cell 
bp  base pair 
C11orf30 chromosome 11 open reading 
frame 30 
CD Crohn’s disease 
CD14 monocyte differentiating antigen 
CD14 
Chr  chromosome 
CI  confidence interval 
CMA1  mast cell chymase  
CNV  copy number variation 
CRNN cornulin 
DNA deoxyribonucleic acid 
EAACI European Association of Allergy 
and Clinical Immunology 
EDC  epidermal differentiation complex 
EMSA electrophoretic mobility shift assay 
EOMES eomesodermin 
FCER1A alpha polypeptide of the high 
affinity receptor I for the Fc 
fragment of IgE 
FLG  filaggrin 
FLG2 filaggrin 2 
GARP glycoprotein A repetitions 
predominant 
GINI German Infant Nutritional 
Intervention Study 
GM-CSF granulocyte-macrophage-colony-
stimulating factor 
GUCY2E guanylat cyclase 2E 
GWAS  genome-wide association study 
HapMap haplotype map 
HGP  Human Genome Project 
HRH4  histamine receptor H4 
HRNR  hornerin 
IF  intermediate filaments 
IgE  immunoglobulin E 
IL  interleukin 
IL4RA  IL4 receptor alpha-chain 
ISAAC International Study of Asthma and 
Allergies in Childhood 
 
IV  ichthyosis vulgaris 
IVL  involucrin 
kD  kilo Dalton 
KLK7 kallikrein-related peptidase 7 
KORA Cooperative Health Research in 
the Region of Augsburg 
LCE  late cornified envelope 
LCR  locus control region 
LD  linkage disequilibrium 
LEKTI lymphoepithelial kazal-type-related 
inhibitor 
LISA Influences of life-style related 
factors on the immune system and 
the development of allergies in 
childhood 
lof  loss-of-function 
LOR  loricrin 
LRRC32 leucine rich repeat containing 32 
LY86 lymphocyte antigen 86 
MAF minor allele frequency 
MALDI TOF MS matrix assisted laser 
desorption/ionisation time of flight 
mass spectrometry 
Mb mega base 
MEF-2A myocyte-specific enhancer factor 
2A 
Mio. Million 
NCBI National Center for Biotechnology 
Information 
NMF/NMS natural moisturizing 
factors/substances 
NOD nucleotide-binding oligomerization 
domain protein 
OR  odds ratio 
PAD pepdidyl-arginin deaminase 
PAMP pathogen-associated molecular 
pattern  
PAR  population attributable risk 
PBL  peripheral blood leukocyte 
PCA  pyrrolidone carboxylic acid
Abbreviations  IX 
PRKRIR protein-kinase, interferon-inducible 
double stranded RNA dependent 
inhibitor, repressor of (P58 
repressor) 
PRR  pattern recognition receptor 
RAD50  DNA repair protein RAD50 
RANTES regulated on activation, normal T-
cell expressed and secreted 
RFLP restriction fragment length 
polymorphism 
RHS  RAD50 hypersensitive site 
RNA  ribonucleic acid 
RPTN repetin 
RT-PCR real time-polymerase chain 
reaction 
S100A  S100 calcium binding protein A 
S. aureus staphylococcus aureus 
SC  stratum corneum 
SCCE stratum corneum chemotryptic 
enzyme 
SCORAD score of atopic dermatitis 
SCTE  stratum corneum tryptic enzyme 
SLE  systemic lupus erythematosus 
SNP  single nucleotide polymorphism 
SPINK5 serine protease inhibitor, Kazal 
type 5 
SPR  small proline rich proteins 
STAT6 signal transducer and activator of 
transcription 6 
STR  short tandem repeat 
TCHH  trichohyalin 
TDT  transmission disequilibrium test 
TEWL  transepidermal water loss 
TGF-beta transforming growth factor beta 
TGM  transglutaminase 
TH1  T-helper cells 1 
TH2  T-helper cells 2 
TLR  toll-like receptor 
TSLP  thymic stromal lymphopoietin 
UCA  urocanic acid 
UCSC  University of California Santa Cruz 
UK  United Kingdom 
UTR  untranslated region 
UV  ultraviolet 
VNTR  variable number of tandem repeats 
WAO  World Allergy Organisation 
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1 Introduction 
1.1 Atopy and atopic diseases 
Although the term “atopy” is relatively new, there are several historic documents which refer to 
“atopic” diseases. Over 2500 years ago, Hippocrates described a condition of an 
undetermined cause characterized as “itching over [one’s] whole body” (Smith 1994). 
Likewise, the Emperor Octavianus Augustus was reported to suffer from “extremely itchy skin, 
seasonal rhinitis and tightness of the chest” by Suetonius (Ring 2005). Formally, the term 
“atopy” (derived from Greek: “atopos”, “not in the right place”) was introduced 1923 by Coca 
and Cooke to describe some phenomena of hypersensitiveness in man (Coca and Cooke 
1923). They considered ‘‘atopy’’ as a hereditary disorder clinically characterized by asthma or 
hay fever, which is associated with immediate-type (wheal-and-flare) skin reactions and which 
is different from ‘‘anaphylaxis’’ as a lack of protection (Portier and Richet 1902), and ‘‘allergy’’ 
as altered reactivity. Since Prausnitz and Küstner had already demonstrated the passive 
transfer of immediate hypersensitivity in man by serum (Prausnitz and Küstner 1921), Coca 
and Grove later designated the causative serum factor as “atopic reagins” (Coca and Grove 
1925). In 1933, Wise and Sulzberger included eczema into the group of atopic diseases 
proposing the term ‘‘atopic dermatitis’’ to denote ‘‘confusing types of localised and generalised 
lichenification, generalised neurodermatitis or manifestation of atopy” (Wise and Sulzberger 
1993). After the identification of “reagins” as immunoglobulin E (IgE) antibodies Pepys defined 
atopy as inherited tendency to produce increased amounts of IgE against low doses of 
environmental allergens (Pepys 1994). His definition therefore not implies the presence of 
clinical symptoms, but describes the patient’s immunologic reaction. Since these years, the 
definition of “atopy” has been a matter of controversy. Recently a working group of the World 
Allergy Organization (WAO) proposed the following definition of atopy “[…] a personal and/or 
familial tendency, usually in childhood or adolescence, to become sensitized and produce IgE 
antibodies in response to ordinary exposures to allergens, usually proteins. As a 
consequence, these persons can develop typical symptoms of asthma, rhinoconjunctivitis, or 
eczema (Johansson, Bieber et al. 2004). 
1.2 Clinical presentation and diagnosis of eczema 
Eczema is a chronic inflammatory skin disease characterized by intense pruritus, dry skin, a 
relapsing course and typical age-related distribution of skin lesions. In infants, eczematous 
lesions usually appear on the scalp (milk-crust) and the cheeks, whereas during childhood the 
flexures, the dorsal parts of the limbs, and the nape are involved. In adolescent and adult 
patients the head, neck and flexures are often affected. Flares are characterized by oozing 
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erythematous patches and plaques. Furthermore, lichenification, recurrent superinfections and 
crusted erosions are common. A lot of patients show characteristic, but not specific atopic 
stigmata, like hyperlinearity of the palms (“ichthyosis hand”), Dennie-Morgan fold (groove of 
the lower eyelid), Herthoge’s sign (lateral rarefaction of the eyebrow), and white 
dermographism (Weidinger and Ring 2006). 
The majority of patients show an onset of disease in early childhood before the age of five, 
often referred to as “early-onset eczema” and a spontaneous remission in early adolescence 
(Williams and Strachan 1998), but the disease also can persist into or start in adulthood (late-
onset eczema), making it one of the most common skin disorders throughout all ages. 
Eczema frequently co-occurs with other atopic disorders such as asthma, rhinitis and food 
allergy, and is often marked by elevated levels of serum IgE and an abnormal IgE-mediated 
response to common allergens (Bieber 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Flexural and abdominal eczema in a child and an infant, respectively. From (Weidinger and 
Ring 2006). 
 
Thus, eczema shows a wide spectrum of clinical presentations both within and between 
patients, and it is still unclear whether it represents a single disorder with different clinical 
manifestations or a group of syndromes with unique or overlapping pathophysiological 
pathways and a rather uniform clinical presentation. Dermatological examinations of the 
specific morphology and distribution of skin lesions and further characteristics like the intense 
pruritus and the chronicity of symptoms are the basis for a medical diagnosis (Weidinger and 
Ring 2006). In the absence of adequate laboratory tests and specific histological features, 
numerous lists of diagnostic criteria have been developed in order to establish a definition. 
Above all, a clear-cut definition of eczema is extremely necessary for the implementation of 
reliable and reproducible epidemiological, clinical, and genetic research. At present, the United 
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Kingdom Working Party’s diagnostic criteria have been most widely validated and appear to 
be applicable and repeatable across all ages and many ethnicities (Table 1). 
However, as shown in a recent review, the ideal set of diagnostic criteria still has to be 
established (Brenninkmeijer, Schram et al. 2008). 
 
Mandatory feature 
 Itchy skin (within the last year)  
In combination with at least three of the following features 
 History of flexural dermatitis 
 Visible flexural dermatitis 
 Age of onset <2 years (for patients >4 years) 
 History of atopy 
 Xerosis 
Table 1: United Kingdom Working Party’s Diagnostic Criteria for the Diagnosis of Atopic Dermatitis. 
 
1.3 Aetiology of eczema 
Eczema is regarded as a multifactorial disease, which results from complex gene-environment 
interactions (Cookson 2001; Hoffjan and Epplen 2005). The variability of its clinical 
presentation between individual patients depends on a variety of different genetic and non-
genetic determinants. 
Environmental trigger factors such as aeroallergens like dust mite, animal dander, and pollen 
have been shown to provoke eczema flares and to influence eczema severity (Schafer, 
Heinrich et al. 1999; Capristo, Romei et al. 2004; Purvis, Thompson et al. 2005) and can 
provoke exacerbations in adult eczema. Allergic sensitization to food allergens, mainly to 
cow’s milk and hen’s egg, which is frequent in infant patients, is also associated with the 
severity of the disease (Hauk 2008). Further factors are recurrent bacterial, fungal and viral 
infections. Eczema patients often exhibit extensive colonization of the skin by bacteria and 
fungi such as Staphylococcus aureus and malassezia. An explanation for this observation 
might be the deficiency of antimicrobial peptides due to the inflammatory micromilieu in the 
skin of eczema affected individuals (Ong, Ohtake et al. 2002; Rieg, Steffen et al. 2005; McGirt 
and Beck 2006; Kisich, Carspecken et al. 2008). Especially persistent colonization with S. 
aureus is frequent in these individuals and might cause flares (Leung 2003; Elias and 
Schmuth 2009). Secretion of staphylococcal superantigens (S. aureus enterotoxins) activates 
macrophages and T cells and the production of enterotoxin-specific IgE antibodies in the host, 
which correlates with eczema severity (Leung 1993; Bunikowski, Mielke et al. 1999). Stress 
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(Schmid-Ott, Jaeger et al. 2001), autoreactivity to human proteins (autoantigens) (Natter, 
Seiberler et al. 1998; Mothes, Niggemann et al. 2005) and other irritant factors like sweat, 
soap or woolly clothing may also contribute to the pathogenesis of the disease. 
Eczema is thought to be part of the syndrome of “atopic diseases”, which are characterized by 
the production of IgE antibodies to ubiquitous allergens. Immunological abnormalities in 
eczema patients involve a systemic IgE-mediated T-helper cell 2 (TH2) dominated immune 
pattern together with a progressive shift from a TH2 immune response in acute lesions to a T-
helper cell 1 (TH1) immune response in chronic lesions (Bieber 2008). For the majority of 
eczema patients IgE mediated allergies play an essential and disease maintaining role (atopic 
or “extrinsic” eczema). Affected individuals show high total serum IgE levels as well as specific 
sensitization against food and aeroallergens (Novak, Kruse et al. 2002; Novak and Bieber 
2003) and an intranasal, bronchial or epicutaneous application of common aeroallergens can 
provoke or worsen eczematous skin lesions (Darsow, Vieluf et al. 1995). 
Nevertheless, like for asthma bronchiale, there exists a significant amount of eczema patients 
without any sign of IgE-mediated sensitization. In particular children <2 years and persons with 
adult-onset eczema are affected by this “intrinsic” or non-atopic form of the disease, and 
present normal IgE serum levels without any sensitization to food or aero-allergens (Novak 
and Bieber 2003; Illi, von Mutius et al. 2004). However, children with early-onset non-atopic 
eczema often become sensitized during the course of the disease, several weeks or month 
after the first manifestation of skin lesions (Novak and Bieber 2003; Illi, von Mutius et al. 2004). 
The estimated frequency of the non-atopic form accounts for 16% - 45% of eczema patients 
(Novak and Bieber 2003). In two multi-centre, multi-national trials wide variation in the pattern 
of allergic sensitization between different countries was observed, with the highest numbers of 
sensitized infants in Australia (83%) and the United Kingdom (UK) (79%), a finding that 
reassembles prevalence for eczema (de Benedictis, Franceschini et al. 2009). There is still an 
ongoing discussion about the question if IgE is a primary causative factor in asthma and 
eczema or if it only represents an epiphenomenon of these phenotypes (Williams and Flohr 
2006; Flohr, Weiland et al. 2008). 
Due to the observation that eczema often precedes the subsequent manifestation of asthma, 
and since eczema has been shown to be a well-established risk factor for asthma, the concept 
of a progressive “atopic march” has been developed, i.e. that in susceptible individuals there is 
a sequential progression from eczema and food allergy to asthma and rhinitis (Wahn and von 
Mutius 2001; Spergel and Paller 2003; Spergel 2005). While sensitization represents a 
plausible link between eczema and asthma, recent research indicates that sensitization might 
as well be a shared epiphenomenon (Novak and Bieber 2003; Illi, von Mutius et al. 2004). 
Recently provided evidence for lung inflammation caused by epidermal produced thymic 
stromal lymphopoietin (TSLP) points towards alternative mechanisms apart from allergic 
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sensitization for the comanifestation of eczema and asthma (He, Oyoshi et al. 2008; Demehri, 
Morimoto et al. 2009; Zhang, Hener et al. 2009) 
The complex pathophysiology of eczema is reflected by the confusing terminology including 
terms such as “atopic eczema”, “atopic dermatitis”, “childhood eczema”, “atopiform dermatitis” 
and “flexural dermatitis” frequently used synonymously in the literature. Following the 
recommendation for a standardized nosology for allergic diseases of the nomenclature 
committee of the WAO (Johansson, Bieber et al. 2004) and the task-force on nomenclature of 
the European Academy of Allergy and Clinical Immunology (EAACI) (Johansson, Hourihane et 
al. 2001), the term “eczema” now includes both subtypes and is used instead of atopic 
eczema/dermatitis. The term “atopic eczema (AE)” solely designates individuals with eczema 
and involved IgE (extrinsic form), whereas the rest, formerly known as “intrinsic” form, is 
referred to as “non-atopic eczema”. However, as pointed out, this division might not 
adequately reflect the natural history of this disease (Bieber 2008), and it has to be considered 
that so far most, if not all, studies on the genetics of eczema were performed prior to these 
suggestions. Additionally, most existing DNA collections have been assembled using older 
definitions. 
To avoid confusion, in this thesis the nomenclature suggested by the WAO is used. 
1.4 Epidemiology of eczema 
The prevalence of eczema has nearly doubled in the last thirty years, and 15-30% of children 
and 2-10% of adults are affected nowadays (Williams and Flohr 2006; Stensen, Thomsen et 
al. 2008). Comprehensive global data on the prevalence of eczema symptoms has been 
provided by the International Study of Asthma and Allergies in Childhood (ISAAC), a 
systematic international record of the prevalence of asthma, eczema and rhinitis involving 
more than 100 countries and 2 Million children. The range of prevalence values for current 
eczema symptoms in the age groups 6-7 and 13-14 years varied from 0.9% in India and 0.2% 
in Tibet to 22.5% in Ecuador and 24.6% in Colombia, respectively (Odhiambo, Williams et al. 
2009). Overall, in the age group of 6-7 years high prevalence values (≥15%) for current 
eczema symptoms were commonly found more often in study centres in Oceania (Australia, 
New Zealand), whereas generally lower values (<5%) were reported for the Indian 
subcontinent, the Eastern Mediterranean Region and Northern and Eastern Europe. In the age 
group of 13-14 year old children Africa and Oceania showed overall higher rates for current 
eczema prevalence in contrast to the Indian subcontinent and participating centres in Northern 
and Eastern Europe with generally low values. Germany itself ranges in the middle of ranked 
prevalence rates with values of approximately 8% for current eczema symptoms in both age 
groups (Odhiambo, Williams et al. 2009). 
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However, prevalence differed strongly between different nations and even between particular 
study centres within the same country or geographical region. The observed differences in 
international and national patterns illustrate the diversity in the global prevalence of this 
disease and shows that eczema represents a major public health issue not only in 
industrialized but also in developing countries. 
A widely favoured explanation for the rising prevalence is the so-called “hygiene-hypothesis”, 
which is based on the epidemiological observation of higher prevalence of eczema in urban 
compared to rural areas. Infections and exposition to microbial antigens during early childhood 
seem to have a protective influence on the formation of eczema and atopic disease (Strachan 
1989; Braun-Fahrlander and Lauener 2003; Zutavern, von Klot et al. 2006) and a relation 
between the growing prevalence and the higher living standard and improved hygienic 
conditions resulting in less frequent parasitic infestation is assumed (Schafer, Meyer et al. 
2005). 
1.5 Evidence for a genetic basis of eczema 
There is a longstanding recognition that asthma, eczema, and rhinitis cluster in families 
(Sneddon 1951; Schaffer 1966), which suggests a strong influence of genetic risk 
components. Nearly one century ago Cooke and van der Veer already suggested a genetic 
component after making the observation of an increased incidence for atopic diseases in first 
degree family members (Cooke and Van der Veer 1916). Parental atopy, in particular eczema, 
is strongly associated with an increased risk for the offspring to develop the disease (Dold, 
Wjst et al. 1992; Wadonda-Kabondo, Sterne et al. 2004). The strongest evidence for the 
importance of genetic factors in atopic disease stems from twin studies. Mono- and dizygotic 
twins are normally exposed to an identical environmental milieu and life style within their 
family, thus providing the possibility of measuring genetic influences broadly independent from 
environmental factors. The concordance rate for eczema among monozygotic twins (0,72-
0,86) has been shown to be significantly higher than for dizygotic twins (0,15-0,23), and 
segregation analyses indicated that genetic components account for more than 70% of the 
variance in susceptibility to the disease (Larsen, Holm et al. 1986; Schultz Larsen 1993; 
Thomsen, Ulrik et al. 2006; van Beijsterveldt and Boomsma 2007). 
Eczema is considered a poly- or oligogenetic disease, resulting from a complex interplay 
between various susceptibility loci in the genome. Unlike monogenic disorders, which are 
caused by mutations in a single gene, eczema seems to arise on the basis of variations in a 
variety of different genes, which do not follow a Mendelian mode of inheritance (Glazier, 
Nadeau et al. 2002). Additionally, parent - of - origin effects have been attributed to eczema. 
Different studies suggested that maternally transmitted alleles are more likely to be associated 
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with disease in the offspring than inheritance from the father (Walley, Chavanas et al. 2001; 
Weidinger, Baurecht et al. 2008). 
1.6 Methods used in the genetic dissection of eczema 
The human DNA sequence between two individuals differs only by approximately 0.1%. These 
differences are mainly based on four types of polymorphic variants: single nucleotide 
polymorphisms (SNPs), microsatellites (short tandem repeats, STRs), restriction length 
fragment polymorphisms (RLFPs) and a variable number of tandem repeat polymorphisms 
(VNTRs). These polymorphic markers, which not necessarily contribute directly to a certain 
disease, are commonly used as proxis for susceptibility loci, and have become the genetic tool 
in the dissection of heritable diseases. 
In general, there are two major approaches to identify genetic variants associated with 
susceptibility to complex traits: linkage analysis and association studies. 
1.6.1 Whole-genome linkage studies 
Genome-wide linkage analysis is a family-based method. Highly polymorphic genetic markers, 
usually microsatellites, which are evenly distributed across the genome, are used to analyze 
co-segregation with the disease in a collection of independent individuals and their parents or 
within a pedigree of many generations. The most common approach is the linkage analysis of 
affected sib pairs. To determine the proportion of parental alleles shared at each marker pairs 
of siblings having a certain disease are genotyped. If there is a significant difference in the 
ratio of shared marker alleles between affected siblings under the assumption of no linkage, 
the region surrounding the marker is linked to the disease. One advantage of this method is 
the independency of any hypothesis, and due to the highly polymorphic nature of 
microsatellites it requires only a small number of markers. On the other hand it is not possible 
to identify specific genes as the linked regions typically encompass several mega bases of the 
genome and might include hundred of different genes. To narrow down the region of peak 
linkage, follow-up analyses including positional cloning with high-density sets of microsatellite 
markers and SNPs have to be conducted. Linkage analyses have been very successful in the 
identification of monogenic disease genes (McKusick 2007), but they have limited power to 
detect small risk genes for complex traits due to epistasis, incomplete penetrance, polygeneity 
or phenotypic heterogeneity. None of the genome-wide linkage studies on eczema performed 
to date has led to the identification of a validated disease gene (see chapter 1.7 Results from 
whole-genome linkage studies in eczema). 
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1.6.2 Association studies 
With the first publication of the Human Genome Project (HGP) in 2001 (McPherson, Marra et 
al. 2001), the determination of the sequence of 3 billion base pairs representing the human 
genome - including newly identified polymorphisms - and their publication in public databases 
it became possible to analyze markers in distinct genes of interest by genetic association 
studies. This approach is not, like linkage studies, limited to a family-based study design, but 
can also analyze the distribution of possible disease markers in unrelated and disease 
affected individuals compared to healthy control subjects (case-control study design) 
(Altshuler, Daly et al. 2008). An association between the genotype and the phenotype is 
assumed if the genetic marker and the disease occur together more often than expected by 
chance. Association studies provide a more powerful tool for detecting common disease 
alleles, even if conferring only a modest disease risk (Risch and Merikangas 1996). 
The most common form of genetic variations detected by the HGP are SNPs, which represent 
over 80% of the genetic variation between individuals. A SNP is a site where a single base 
substitution occurs at a frequency of at least 1% in the population. Approximately one out of 
every 200 base pairs in the human genome is a SNP. These variants are commonly biallelic 
and less polymorphic as microsatellites, but they are much more frequent and more easily 
scored with automatic methods than the latter. Moreover, SNPs often occur in coding (gene) 
regions of the genome. Terms to classify SNPs due to their genomic position are coding and 
non-coding, non-synonymous (amino acid change) and synonymous (no amino acid change). 
The majority of SNPs are non-functional and therefore result in neutral phenotypic outcomes. 
However, a subset of SNPs can predispose individuals to disease, or influence its severity, 
progression or individual response to medicine. At the molecular level, these functional SNPs 
can affect the human phenotype by interfering on both levels of the protein synthesis 
machinery: non-coding SNPs may disrupt transcription factor binding sites, splice sites and 
other regulatory elements on the transcriptional level, whereas coding SNPs can cause an 
amino acid change and alter the functional or structural properties of the translated protein. 
Together with DNA copy number variations (CNVs), SNPs have become one of the most 
actively researched areas of genomics in recent years (Feuk, Carson et al. 2006). Until 
recently, based on technical limitations, association studies have been focused on the analysis 
of candidate genes, which are selected because of their possible involvement in disease 
pathogenesis due to their function or because of their location in regions with observed linkage 
in prior genome-wide linkage scans (positional/functional candidate genes) (Tabor, Risch et al. 
2002). However, candidate gene studies are prone to type I (false positive results) and type II 
errors (false negative results), and an appropriate and stringent study design including 
independent replication of results is of great importance to achieve solid results. There are 
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many potential pitfalls in candidate gene association studies such as a lack of power to detect 
a true association (too small sample size), clinical heterogeneity of the trait in question, which 
leads to an inhomogeneous study cohort, inappropriate selection of control individuals or the 
general use of inappropriate statistical models and correction methods for multiple testing 
(Glazier, Nadeau et al. 2002; Lohmueller, Pearce et al. 2003; Rogers, Raby et al. 2009). 
Generally, case-control designs are prone to confounding because of population stratification, 
i.e. ethnic/racial heterogeneity of study subjects (Ober and Hoffjan 2006). Population 
stratification describes the mixture of two or more subpopulations within a study cohort. If 
these subpopulations differ in allele frequencies, stratification might lead to false positive 
results (Figure 2). The Transmission-Disequilibrium-Test (TDT) based on family collections 
(case-parent trio design) has the advantage of being unaffected by population stratification. 
Provided that at least one of the parents is heterozygous for a given allele, the TDT analyses if 
this allele is more often transmitted than untransmitted to the affected offspring (Knapp 1999). 
Because non-transmitted parental alleles serve as internal controls, reliable ethnic 
homogeneity is given (Spielman, McGinnis et al. 1993). 
 
 
Figure 2: The effect of population stratification at a SNP locus. If the sample group under 
examination consists of two genetically inhomogeneous subpopulations, allele frequencies differ 
between cases and controls without true association between genotype and phenotype. In the given 
example proportion of population 2 is higher within the case group compared to controls, and 
consequently allele frequency of genotype “aa” is also higher. From (Marchini, Cardon et al. 2004) 
Candidate gene association studies have been supplemented lately by genome-wide 
association approaches. Genotyping-data from the International Haplotype Map (HapMap) 
Project (International HapMap Consortium 2005), which has been extended quite recently by 
resequencing-data of the 1000 Genomes Project (http://www.1000genomes.org) together with 
Introduction   10 
the development of chip-based high-throughput genotyping platforms make it now possible to 
analyze up to 2,5 Million SNPs simultaneously and hypothesis-free. And the next generation of 
genotyping microarrays has already been announced, allowing the analysis of up to 5 Mio. 
variants per human sample. As a number of 17.9 Mio. SNPs in the human genome is 
annotated in public data bases (ensemble release 58, GRCh 37, 
http://www.ensembl.org/Homo_sapiens/Info/StatsTable), only methodological problems limit 
the coverage, and there are discussions about the 1000$ genome including genetic variations 
in toto (Bennett, Barnes et al. 2005; Service 2006; von Bubnoff 2008). 
One important observation of the HapMap project revealed the genome to be organized in 
blocks of SNPs in strong linkage disequilibrium (LD) with one another. So far the majority of 
GWAS are based on a limited set of SNPs, which is supposed to transfer additional 
information on other common polymorphisms in the human genome through LD-based 
tagging. LD refers to non-independent inheritance of alleles, e.g. SNPs, at two or more loci, 
not necessarily located on the same chromosome. This non-random association of different 
alleles normally located at two different sites nearby each other (Wall and Pritchard 2003) is 
mainly influenced by the rate of recombination between these two sites, but also by mutation 
and genetic drift. The degree of LD is normally higher for shorter distances between two 
alleles, since the distance is directly linked to the probability of recombination events occurring 
between the two loci. 
 
Figure 3: Schematic illustration of formation and erosion of LD structures. (a) shows a 
polymorphic locus with alleles A and a. (b) With the occurrence of a new SNP (Bb) at a nearby site, the 
mutant allele b is located on a single chromosome, which additionally bears either allele A or a of the 
first locus. In the illustrate example the new haplotype Ab (green chromosome) originates. Hence, allele 
b only occurs in combination with allele A. (c) Due to recombination the fourth possible haplotype is 
created (d), association between the two loci is disrupted and LD among the markers declines with 
increasing frequency of the recombinant chromosome in the population. From (Ardlie, Kruglyak et al. 
2002) 
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Common statistical measurements for LD are D’ and r2 ranging between values 0 and 1, with 0 
indicating complete equilibrium or independent transmission and 1 complete disequilibrium or 
dependent transmission. The r2 measure is called correlation coefficient and depends, in 
contrast to D’ additionally on the frequency of alleles. The LD-structure in a region of interest, 
e.g. a gene, is essential for genetic association approaches. Two or more SNPs showing a 
high r2 value are supposed to provide redundant information in terms of the individual 
genotype, and allow a maximal coverage of interesting genes with a minimal effort in 
experimental genotyping. 
For the same reason declarations about associations between certain SNPs and certain 
phenotypes have to be handled with care, as the variant showing association might not be 
itself the causative variant with functional effect, but only in LD with the latter. 
GWAS have already led to the identification of numerous new and robust susceptibility loci for 
many complex diseases (Frazer, Murray et al. 2009) and represent a very useful tool for the 
further dissection of complex traits. However, GWAS, like candidate gene association studies, 
are always dependent on an appropriate study design in terms of study sample size, adequate 
selection of cases and controls, stringent statistical analysis and reproducibility of results. 
1.7 Results from whole-genome linkage studies in eczema 
Up to date six genome-wide linkage scans for eczema have been reported pointing towards 
several possible eczema-linked regions. Major findings were a region on chromosome 3q21 
detected in families of mainly German origin (Lee, Wahn et al. 2000) and the loci 1q21 and 
17q25 strongly linked to eczema in a British population (Cookson, Ubhi et al. 2001). On 
chromosome 1q21 resides the EDC and the Keratin-Type I-cluster is located on chromosome 
17q25. Both regions harbour gene clusters known to cause genodermatoses through 
perturbance of epidermal differentiation and function (Irvine and McLean 2003). Further 
studies in Swedish, Danish and Japanese families on genome wide linkage reported additional 
findings for 3p24-22, 18q21, 3p26-24 and 15q21 (Bradley, Soderhall et al. 2002; Haagerup, 
Bjerke et al. 2004; Enomoto, Noguchi et al. 2007). Interestingly, for the majority of regions 
linkage to psoriasis, a chronic inflammatory disorder of the skin, which is rarely linked with 
eczema, rather than to allergic asthma has been reported (Cookson, Ubhi et al. 2001). 
With the exception of FLG, which partly underlies the significant linkage to chromosome 1q21 
(Morar, Edster et al. 2007), the responsible disease genes for the remaining loci are still not 
known. 
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1.8 Results from candidate gene association studies in eczema 
Based on the assumption that the primary defect in eczema is immunological and prior to the 
discovery of FLG (see below), for many years candidate genes involved in immune regulation 
and signalling have been investigated, such as genes encoding proinflammatory molecules, 
which are thought to promote TH2 immune responses, as well as genes that had been 
associated with asthma and/or atopy. 
To date, more than 40 associated candidate genes have been reported in literature (Barnes 
2010), but only very few proposed associations could be replicated in at least one independent 
study, and even for replicated genes at the same time a considerable number of negative 
reports exists (Table 2). 
In contrast to these mainly immunological susceptibility genes only filaggrin, appears to 
present a strong and consistent eczema risk gene. The first report of association between FLG 
and ichthyosis vulgaris (IV) appeared in 2006 (Smith, Irvine et al. 2006), followed by the 
identification of several loss-of-function mutations in patients with eczema (Palmer, Irvine et al. 
2006). In the meantime an impressive series of more than 20 independent replication studies 
conducted subsequently after the first replication included in this thesis was performed (Table 
2). Scientific evidence for this gene as one of the strongest risk factors for a complex allergic 
disease is overwhelming. Due to the discovery of FLG, susceptibility genes for eczema are 
now divided into two major functional groups: genes contributing to epidermal or epithelial 
structures and genes encoding immune regulatory proteins: 
1.8.1 Immunoregulatory genes 
Genes involved in immune dysregulation commonly fall into the two major groups of antigen 
presentation and cell-mediated/humoral immune response, and cell signalling/cellular 
movement. Several candidate genes have been identified in the cytokine cluster on 
chromosome 5q31-33, which contains a family of functionally related cytokines regulating IgE-
synthesis, like interleukin (IL)-3, IL-4, IL-5, IL-13 and the granulocyte-macrophage-colony-
stimulating factor (GM-CSF). IL-4, IL-5 and IL-13 are produced by TH2 cells, and the latter two 
cytokines are known to increase the production of IgE. 
One of the most consistent associations has been reported for interleukin-13, where two 
functional polymorphisms in the promoter region and in exon 4 have been associated with a 
variety of atopy-related disorders. IL-13 has been shown to be overexpressed in eczema 
lesions, especially in the non-atopic form (Jeong, Ahn et al. 2003; Tazawa, Sugiura et al. 
2004). 
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Observed increase in the transcriptional activity of interleukin-4 due to a mutation (-590 C/T) 
in the promoter of this gene seems to predispose for eczema (Kawashima, Noguchi, Arinami, 
Yamakawa-Kobayashi et al. 1998), too. Association with a gain-of-function mutation in the α- 
subunit of the IL-4 receptor (IL4RA) located on chromosome 16q12 additionally could 
enhance IL-4 mediated effects (Hershey, Friedrich et al. 1997). 
Mutations in the promoter region of RANTES (regulated on activation, normal T-cell expressed 
and secreted) and association with eczema has been reported by different studies (Nickel, 
Casolaro et al. 2000; Bai, Tanaka et al. 2005; Tanaka, Roberts et al. 2006). This chemokine is 
located within the C-C chemokine cluster on chromosome 17q11-12, and belongs to the family 
of chemotactic cytokines, small signalling proteins regulating leukocyte trafficking at site of 
inflammation. RANTES has been shown to be overexpressed in lesional skin of eczema 
patients (Kato, Pawankar et al. 2006) and attracts monocytes, eosinophils, basophils and 
lymphocytes. 
CMA1 encoding the enzyme mast cell chymase, is located on chromosome 14q11.2 and 
represents the major secreted serine protease of mastcells. Together with histamine and 
tryptase it seems to play a key role in inflammation, bronchial hyperresponsiveness and tissue 
remodelling and is therefore an excellent candidate gene not only for atopy but also for 
eczema. Association between variants in the promoter region of CMA1 and eczema have 
been reported in several studies (Mao, Shirakawa et al. 1996; Mao, Shirakawa et al. 1998; 
Tanaka, Sugiura et al. 1999; Weidinger, Rummler et al. 2005) and an elevated expression 
level has been noted in lesional and non-lesional skin of affected individuals (Jarvikallio, 
Naukkarinen et al. 1997; Badertscher, Bronnimann et al. 2005). 
NOD1 (nucleotide-binding oligomerization domain protein 1, also designated CARD4) is 
located on chromosome 7p14-15, belongs to the family of so-called pattern-recognition 
receptors (PRRs) and responds to pathogen-associated molecular patterns (PAMPs) as part 
of the innate immunity host defence. This receptors are either localized in the cell membrane 
like e.g. Toll-like receptors (TLRs) or CD14 or cytosolic proteins like NOD1 and NOD2 
(Inohara, Ogura et al. 2001; Athman and Philpott 2004). Association with eczema and/or 
increased total serum IgE levels has been reported for different variants in this gene 
(Weidinger, Klopp et al. 2005). 
1.8.2 Epithelial barrier genes 
Another involved gene in the cytokine cluster (5q32), which does not belong to immunological 
candidates, seems to be SPINK5 (serine peptidase inhibitor, Kazal type 5), which encodes a 
putative serine protease inhibitor called LEKTI (or LETK1; Lympho-Epithelial Kazal Type 
Inhibitor). The protein was shown to be expressed, amongst others, in the epidermis, mucosal 
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epithelia and organs of the immune system like thymus and lymph nodes (Magert, 
Kreutzmann et al. 2002). LEKTI appears to be responsible for the inhibition of several serine 
proteases like Trypsin, Plasmin, Kathepsin G and human neutrophilic elastase, and additional 
points of attack like allergens with serine protease activity (pollen, components of faeces of 
house dust mite), microbial proteinases, and mastcell tryptase are under discussion (Walley, 
Chavanas et al. 2001; Magert, Kreutzmann et al. 2002; Bitoun, Micheloni et al. 2003; Mitsudo, 
Jayakumar et al. 2003). Most importantly, it is supposed to interact with the stratum corneum 
chymotryptic enzyme (SCCE) (Komatsu, Takata et al. 2002) and the stratum corneum tryptic 
enzyme (SCTE) that are involved in desquamation and inflammation. Both enzymes exhibit an 
increased expression in eczema patients probably pointing out to a shift in the equilibrium 
between these proteases and their inhibitor LEKTI. Of note, proteolytic activation of 
profilaggrin, the precursor of filaggrin, by serine proteases is supposed to be regulated by 
LEKTI. SPINK5 was identified by Chavanas et al (Chavanas, Bodemer et al. 2000; Chavanas, 
Garner et al. 2000) as the cause of Netherton syndrome, an autosomal-recessive disease 
marked by an epidermal barrier disruption and different polymorphisms have been shown to 
be associated with eczema and asthma in combination with eczema (Walley, Chavanas et al. 
2001; Kato, Fukai et al. 2003; Nishio, Noguchi et al. 2003; Kabesch, Carr et al. 2004). 
Filaggrin (FLG) is located within the EDC on chromosome 1q21.3, a dense cluster of 
approximately 50 genes mainly encoding proteins involved in the terminal differentiation of the 
epidermis (Toulza, Mattiuzzo et al. 2007). As already mentioned before, chromosome 1q21 
has been shown to be linked to eczema, psoriasis and IV, the latter of which are two common 
monogenic keratinisation disorders, which are characterized, like eczema, through dry skin 
and stratum corneum (SC) and permeability barrier abnormalities (Linde 1992; Tabata, 
Tagami et al. 1998; Walley, Chavanas et al. 2001). FLG seems to be the susceptibility gene 
underlying the linkage signal on chromosome 1q21, and until now, represents the only known 
responsible disease gene for observed linkage with eczema. 
The denomination filaggrin (filament aggregating protein) for a protein isolated from stratum 
corneum and interacting with intermediate filaments (IF) appeared on the scientific scene in 
1981 (Steinert, Cantieri et al. 1981). FLG represents a structural protein with key functions in 
the formation and maintenance of the cornified envelope, a fact that makes it indispensable for 
preventing the penetration of environmental agents like microbes or allergens into the 
organism and, on the other hand, for controlling transepidermal water loss (TEWL) (Candi, 
Schmidt et al. 2005; Proksch, Brandner et al. 2008). Profilaggrin is expressed as a ~400 kilo 
Dalton (kD) inactive precursor protein in the stratum granulosum of the epidermis (Figure 4). 
It’s most important feature, exon 3, is composed of tandem repeats, encoding the functionally 
active FLG monomers. These FLG repeats are identical in size (324 amino acids (aa)), but 
show some differences in composition ((Gan, McBride et al. 1990). Three different alleles with 
Introduction   15 
10, 11 or 12 repeats have been shown to exist in the general population (Smith, Irvine et al. 
2006). Upon cornification of keratinocytes profilaggrin is proteolytically cleaved into 37 kD 
filaggrin subunits. These monomers lead to a dense bundling of keratin intermediate filaments, 
flattening the keratinocytes during their differentiation into corneocytes (Presland, Haydock et 
al. 1992) (Figure 5). Concurrently, the amino (N)-terminus of the protein is translocated into 
the cell nucleus, where it supposed to be responsible for apoptotic processes (Ishida-
Yamamoto, Takahashi et al. 1998; Pearton, Dale et al. 2002). 
 
 
Figure 4: Structure of Profilaggrin: The N-terminus consists of two distinct domains: a conserved 
S100-like domain and a less conserved cationic B-domain followed by an imperfect FLG-unit and 10-12 
almost identical FLG monomers. The C-terminus contains a truncated FLG-unit and a unique peptide of 
23 amino acids. There are different size variants of the human FLG gene in the population, which have 
resulted from duplications of repeat 8 and/or repeat 10. It is likely that size variants involving other 
repeats also exist. A lower number of repeats has been reported to be associated with dry skin (Ginger, 
Blachford et al. 2005). From (Rodriguez, Illig et al. 2008). 
Together with the lipid envelope, the cornified envelope is formed constituting the mortar and 
brick structure of the epidermis. Additionally, degradation products of filaggrin, free 
hygroscopic amino acids and their derivates, are thought to serve as natural moisturizers of 
the skin (NMF, natural moisturizer factors) (reviewed in (Rodriguez, Illig et al. 2008)) and 
possibly as protection against ultraviolet (UV) radiation (Sandilands, Sutherland et al. 2009). 
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Figure 5: Profilaggrin, the precursor of filaggrin, is expressed in the granular layer of the skin and stored 
in its insoluble form in keratohyalin granules. Upon an increase of the intracellular Ca2+-level during 
differentiation of keratinocytes in the stratum granulosum of the epidermis, the granules release the 
precursor protein, which is subsequently dephosphorylated and proteolytically cleaved into functionally 
active monomers. The functional FLG subunits lead to an aggregation of keratin intermediate filaments, 
thereby promoting transformation of keratinocytes into corneocytes, which constitute the stratum 
corneum. The insoluble keratin matrix is formed by crosslinking of the cytoskeleton by 
transglutaminases (TGMs). Deimination via pepdidylarginine-deiminases (PADs) and conversion of 
arginine into citrullin residues promotes further degradation. Subsequent proteolysis by different 
proteases produces a pool of hygroscopic amino acids and their derivates, like pyrrolidone carboxylic 
acid (PCA) and urocanic acid (UCA) (from (Sandilands, Sutherland et al. 2009)). 
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Although more than 20 years ago FLG was suspected for the first time to be involved in 
different keratinisation disorders like IV, and the finding that its expression is clearly reduced in 
the epidermis of individuals with this disease (Fleckman, Dale et al. 1985; Sybert, Dale et al. 
1985; Fleckman, Holbrook et al. 1987; Nirunsuksiri, Presland et al. 1995; Fleckman and 
Brumbaugh 2002) in depth analysis of this gene revealed to be quite difficult because of its 
repetitive structural nature (Sandilands, Terron-Kwiatkowski et al. 2007). In 2006 Irwin McLean 
and his group finally managed to comprehensively sequence the entire FLG gene and to show 
several mutations to be the cause of IV (Sandilands, O'Regan et al. 2006; Smith, Irvine et al. 
2006). Eczema and IV, which is supposed to be the most frequent monogenic skin disorder 
based on abnormal epidermal differentiation, share a lot of clinical characteristics and are 
associated with each other (Wells 1966). Subsequently the same group detected significant 
associations between the same variants and eczema in independent, but relatively small and 
on the basis of asthma recruited cohorts (Palmer, Irvine et al. 2006). 
The great majority of the more than 30 identified variants in the FLG gene have a frequency of 
less than 1% or are family specific/private mutations. The two most prevalent null mutations 
R501X and 2282del4 show carrier frequencies of <6% in different independent German 
population-based studies (Novak, Baurecht et al. 2007; Chapter 2.3). 
 
 
Figure 6: Structure of the human FLG gene. Like other members of the S100-‘fused type’ gene family 
FLG shares a conserved gene structure consisting of three exons. Exon 1 consists of untranslated 
sequence only, exon 2 contains the start codon and the unusually large exon 3 (12753bp) encodes 
most of the N-terminal domain and 10-12 filaggrin monomers. Most prevalent mutations are depicted in 
red, family specific or private mutations in black and variants detected in Asian populations only in blue. 
Not all mutations identified up to date are included for better overview. From (Rodriguez, Illig et al. 
2008). 
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Interestingly, frequency appears to increase from South to North Europe, which might reflect 
ethnic differences. In populations from UK and Ireland FLG lof-mutations seem to be more 
prevalent compared to continental Europe (Smith, Irvine et al. 2006; Barker, Palmer et al. 
2007; Sandilands, Terron-Kwiatkowski et al. 2007; Brown, Relton et al. 2008; Rice, Patel et al. 
2008; Weidinger, Baurecht et al. 2008) but extremely low in an Italian case-control population, 
which represents the only analysis in South European individuals and furthermore the only 
negative association study on FLG and eczema published so far (Giardina, Paolillo et al. 
2008). Until quite recently, none of the reported and associated FLG null alleles could be 
found in public databases (R501X is now included as rs61816761 in the National Center for 
Biotechnology Information (NCBI), dbSNP build 130, http://www.ncbi.nlm.nih.gov/). 
In Asian populations significant associations of eczema and IV with 18 identified FLG null 
alleles have been observed, too, but mutations seem to be highly population specific. Of the 
20 described loss-of-function variants found in the European population, the majority with the 
exception of four observed heterozygous carriers of R501X (Ching, Hon et al. 2009) could not 
be found in Asian individuals of Japanese, Korean and Singaporean Chinese Populations 
(Nomura, Sandilands et al. 2007; Enomoto, Hirata et al. 2008; Hamada, Sandilands et al. 
2008; Nomura, Akiyama et al. 2008; Hsu, Akiyama et al. 2009) and vice versa. However, this 
ethnic group seems to have its own exclusive null mutations showing the same strong impact 
on the development of eczema. All reported variants are frameshift or nonsense mutations 
leading to a premature translation stop and hence truncation of the profilaggrin molecule. The 
two most common mutations R501X (a nonsense mutation of the arginine codon 501 to a stop 
codon) and 2282del4 (a frameshift mutation at position 2282 due to a four base pair (bp) 
deletion) in the first filaggrin repeat impede any filaggrin synthesis from these alleles. As the 3’ 
gene sequence seems to be important for posttranslational processing into functional filaggrin 
subunits, even variants located in this region prevent or reduce production of free filaggrin in 
the stratum corneum (Sandilands, O'Regan et al. 2006; Sandilands, Terron-Kwiatkowski et al. 
2007). 
In flaky tail (ft/ft) mice, the corresponding mouse model, which resulted from a spontaneous 
mutation, loss of profilaggrin and filaggrin leads to dry and flaky skin, paw constrictions in the 
neonatal period and annular tail (Lane 1972; Presland, Boggess et al. 2000). A homozygous 
frameshift mutation described as a 1bp deletion in the murine FLG gene seems to be the 
reason for insufficient filaggrin production in this mouse model, and can be equated with the 
null mutations found in human FLG (Fallon, Sasaki et al. 2009). 
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Gene Location Phenotype(s) Number of subjects* Variant(s) Association Reference. 
IL13 5q31 
childhood AE 52/288 Canadians rs20541 yes (He, Chan-Yeung et al. 2003) rs1800925 no 
AE 238/104 Dutch rs1800925 yes (Hummelshoj, Bodtger et al. 2003) 
AE 185/102 Japanese rs20541 yes (Tsunemi, Saeki et al. 2002) rs1800925, rs1881457 no 
AE 187/98 Germans rs20541 yes (Liu, Nickel et al. 2000) 
AE 94/186 Chinese rs1800925, rs1881457 no (Chang, Lee et al. 2006) 
childhood AE 178/1358 British rs1800925, rs2066960, rs1295686, rs20541, rs1295685 no (Arshad, Karmaus et al. 2008) 
IL4 5q31 
childhood AE 88 Japanese families rs2243250 yes (Kawashima, Noguchi et al. 1998) 
childhood AE 76+25 Australian families rs2243250, rs2070874, haplotypes no (Elliott, Fitzpatrick et al. 2001) 
AE 190/116 Japanese rs2243250 no (Tanaka, Sugiura et al. 2001) 
AE severity 406 Swedish families rs2243250 yes (Soderhall, Bradley et al. 2002) 
extrinsic AE 60/30 Germans rs2243250 yes (Novak, Kruse et al. 2002) 
early-onset AE  
(<2 years) 52/496 Canadians 
rs2243250 (haplotype with IL13 
variants)) yes (He, Chan-Yeung et al. 2003) 
AE 94/186 Chinese rs2243250, rs2070874 no (Chang, Lee et al. 2006) 
SPINK5 5q32 
Childhood AE 148+78 British families rs2303067 yes (Walley, Chavanas et al. 2001) rs2303063, rs2303064 no 
AE+asthma 41 Japanese families rs2303067, rs2303063, rs2303064, rs17860502, rs2303070 yes (Nishio, Noguchi et al. 2003) 
AE 124/110 Japanese 
rs2303067, rs2303063, rs2303061, 
rs2303062, rs2303066, rs2303068 yes (Kato, Fukai et al. 2003) 
rs2303063, rs2303065 no 
AE 308 German families rs2303067, rs2303063, rs2303064, rs17860502 no (Folster-Holst, Stoll et al. 2005) 
AE 99/102 French rs2303067 no (Hubiche, Ged et al. 2007) 
AE 486 German families 
rs2303067 
yes 
(Weidinger, Baurecht et al. 2008) AE 773/3992 Germans no childhood AE 418/552 Irish/UK 1583/7746 UK 
childhood AE 220/1161 Germans rs2303067 no (Kabesch, Carr et al. 2004) 
AE+asthma 78/200 Dutch rs2303067, rs2303063, rs3756688 no (Jongepier, Koppelman et al. 2005) 175 Dutch families 
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NOD1 
(CARD4) 7p14-15 
adult AE 457/1417 Germans rs2736726, rs2075817, haplotypes yes 
(Weidinger, Klopp et al. 2005) AE 189 German families rs2975632, rs2075822, rs2907749, rs2907748 yes 
AE 392/297 Germans haplotypes, SNP-SNP interaction yes (Macaluso, Nothnagel et al. 2007) 
CMA1 14q11.2 
adult AE 100/100 Japanese rs1800175 yes (Mao, Shirakawa et al. 1996) 
childhood AE 145/851 Japanese rs1800175 yes (Mao, Shirakawa et al. 1998) 
AE 100/101 Japanese rs1800175 no (Kawashima, Noguchi et al. 1998) 
intrinsic AE 47/100 Japanese rs1800175 yes (Tanaka, Sugiura et al. 1999) 
AE 70/100 Italians rs1800175 no (Pascale, Tarani et al. 2001) 
adult AE 242/1875 Germans 
rs1800175 yes 
(Weidinger, Rummler et al. 2005) rs1956923, rs5244, rs5246, rs5247, 
rs5248, rs5250 no 
IL4RA 16p12-11 
AE 101/75 Japanese 
rs2057768, rs2107356, rs8060798, 
rs8060938, rs12927172 yes (Hosomi, Fukai et al. 2004) 
rs12927543 no 
adult AE 27/29 Japanese rs1805011 yes (Oiso, Fukai et al. 2000) rs1805010, rs1805012 no 
Infantile flexural 
AE 245/1051 British rs1801275 yes (Callard, Hamvas et al. 2002) 
extrinsic AE 302/122 Japanese rs1805010, rs1805011, rs1801275 no (Tanaka, Sugiura et al. 2001) 
AE 94/186 Chinese rs1805011, rs2234898, rs1805012, rs1801275, rs1805015 no (Chang, Lee et al. 2006) 
RANTES 17q11.2 
childhood AE 188/98 Germans rs2107538 yes (Nickel, Casolaro et al. 2000) 
childhood extrinsic 
AE 128/303 Hungarian rs2107538, rs2280788 no (Kozma, Falus et al. 2002) 
AE 62/14 Japanese rs2107538 yes (Bai, Tanaka et al. 2005) 
extrinsic AE 389/177 Japanese rs2107538, rs2280788 yes (Tanaka, Roberts et al. 2006) 
FLG 1q21.3 
AE, extrinsic AE, 
childhood AE, 
adult AE, 
AE+asthma 
> 6000/> 27000 
> 3000 families 
Europeans, European-
Americans, Japanese, 
Chinese, Koreans 
R501X, 2282del4, etc. yes 
(Palmer, Irvine et al. 2006), 
> 20 reports reviewed in 
(Rodriguez, Baurecht et al. 2009) 
Table 2: Published candidate genes for which association with eczema (designated AE due to limitation of space) has been reported in at least two independent 
studies. * Number of cases/controls, cases/cohort or families. 
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1.9 Aims 
The aetiology of eczema is complex, as different genetic as well as environmental factors 
contribute to the disease. This complexity displays a major challenge to the dissection of 
underlying mechanisms. Since only a few genes have been identified to influence 
manifestation of eczema, and as more susceptibility genes are supposed to exist, this work 
addresses the genetic impact on eczema by identifying and describing novel risk variants 
and genes for the disease. 
As replication studies of reported associations between genetic variants and complex 
diseases often unmask false positive results, the previously described loss-of-function 
polymorphisms in the filaggrin gene and their association with eczema should be confirmed 
in a first independent replication study within this thesis. In order to further delineate the role 
of FLG mutations in eczema pathogenesis and subphenotypes (atopic and non-atopic form), 
intermediate phenotypes like serum IgE levels, and related atopic traits like asthma and 
rhinitis several association studies including family-based and case-control approaches will 
be performed. Concurrently its impact in epidemiological terms on eczema and atopic traits 
in the general population will be determined in a large population-based cross-sectional 
study population. Refinement of the risk profile of FLG null alleles will be achieved by a meta-
analysis including the data of 24 association studies on eczema and asthma published until 
November 2008.  
To gain further insights in the genetic architecture of eczema and its endophenotype IgE and 
to unravel novel susceptibility loci two unbiased genome-wide association studies should be 
conducted. These hypothesis-free approaches are projected in various large and well 
phenotyped cohorts with the help of newly developed high throughput SNP genotyping 
platforms and results will be concurrently validated in different independent replication 
cohorts. 
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2 Results 
This work includes and is based on the following publications: 
 
I Weidinger S, Illig T, Baurecht HJ, Irvine AD, Rodríguez E, Diaz-Lacava A, Klopp N, 
Wagenpfeil S, Zhao Y, Liao H, Lee SP, Palmer CNA, Jenneck C, Maintz L, Hagemann T, 
Behrendt H, Ring J, Nothen MM, McLean WHI, Novak N. Loss-of-function variations 
within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. J 
Allergy Clin Immunol 118(1):214-219, 2006. (Chapter 2.1) 
 
 
II Weidinger S, Rodríguez E, Stahl C, Wagenpfeil S, Klopp N, Illig T, Novak N. Filaggrin 
mutations strongly predispose to early-onset and extrinsic atopic dermatitis. J Invest 
Dermatol 127:724-726, 2007. (Chapter 2.2) 
 
 
III Weidinger S, O’Sullivan M, Illig T, Baurecht HJ, Depner M, Rodríguez E, Ruether A, 
Klopp N, Vogelberg C, Weiland SK, McLean WHI, von Mutius E, Irvine AD, Kabesch M. 
Filaggrin mutations, atopic eczema, hay fever and asthma in children. J Allergy Clin 
Immunol 121(5):1203-1209, 2008. (Chapter 2.3) 
 
 
IV Rodríguez E, Baurecht H, Herberich E, Wagenpfeil S, Brown SJ, Cordell HJ, Irvine AD, 
Weidinger S. Meta-analysis of filaggrin polymorphisms in eczema and asthma: Robust 
risk factors in atopic disease. J Allergy Clin Immunol, 123(6):1361-70, 2009. (Chapter 
2.4) 
 
 
V Esparza-Gordillo J, Weidinger S, Fölster-Holst R, Bauerfeind A, Ruschendorf F, Patone 
G, Rohde K, Marenholz I, Schulz F, Kerscher T, Hubner N, Wahn U, Schreiber S, Franke 
A, Vogler R, Heath S, Baurecht H, Novak N, Rodríguez E, Illig T, Lee-Kirsch MA, 
Ciechanowicz A, Kurek M, Piskackova T, Macek M, Lee YA, Ruether A. A common 
variant on chromosome 11q13 is associated with atopic dermatitis. Nat Genet, 41(5):596-
601, 2009. (Chapter 2.5) 
 
 
VI Weidinger S, Gieger C, Rodríguez E, Baurecht HJ, Mempel M, Klopp N, Gohlke H, 
Wagenpfeil S, Ollert M, Ring J, Behrendt H, Heinrich J, Novak N, Bieber T, Krämer U, 
Berdel D, von Berg A, Bauer CP, Herbarth O, Koletzko S, Prokisch H, Mehta D, Meitinger 
T, Depner M, von Mutius E, Liang L, Moffatt M, Cookson W, Kabesch M, Wichmann HE, 
Illig T. Genome-wide scan on total serum IgE levels identifies FCER1A as novel 
susceptibility locus. PLoS Genet 4(8):1-9, 2008. (Chapter 2.6) 
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2.1 Loss of function variations within the filaggrin gene predispose for atopic 
dermatitis with allergic sensitization 
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2.2 Filaggrin mutations strongly predispose to early-onset and extrinsic atopic 
dermatitis 
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2.3 Filaggrin mutations, atopic eczema, hay fever and asthma in children 
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2.4 Meta-analysis of filaggrin polymorphisms in eczema and asthma: Robust 
risk factors in atopic disease 
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2.5 A common variant on chromosome 11q13 is associated with atopic 
dermatitis 
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2.6 Genome-wide scan on total serum IgE levels identifies FCER1A as a novel 
susceptibility locus 
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2.7 Summary of results 
 
In the following the main findings of each study are shortly summarized: 
I.  Two recently discovered risk alleles for eczema in the filaggrin gene on chromosome 
1q21.3, R501X and 2282del4, were independently replicated for the first time and 
additionally analyzed regarding their relevance for different subtypes of eczema and 
related allergic and intermediate phenotypes. Both variants were significantly 
overtransmitted from parents to affected offspring in a set of 476 German families. The 
combined genotype Aa (heterozygous carriers of at least one mutant allele) showed 
strong association with eczema (OR 2.73; P 5.1x10-8), total serum IgE levels (P 9,8x10-8), 
allergic sensitization (P 2.3x10-7), asthma a secondary trait (P 0.0003), atopic eczema (P 
9.3x10-8), and the atopy stigmata palmar hyperlinearity (P 5.9x10-6). No association could 
be seen for the non atopic and early onset forms of eczema and analysis of a possible 
parent of origin effect was negative (chapter 2.1). 
II.  For verification of association results FLG variants R501X and 2282del4 were 
analyzed in a second study sample consisting of 272 independent eczema cases and 252 
population-based controls from the cross sectional KORA S4 study (Cooperative Health 
Research in the Region of Augsburg, Survey 4). All previous results could be replicated 
and additional subphenotypes were shown to be strongly influenced by FLG loss-of-
function mutations. 
Confirmation of associated traits for the combined genotype included eczema (OR 3.53 
[95% Confidence Interval (CI) 1.92-6.48]; P 4.9x10-5), atopic eczema (OR 3.66 [95%CI 
1.96-6.83]; P 4.6x10-5), asthma in combination with eczema (OR 5.69 [95%CI 2.76-11.73]; 
P 2.5x10-6), and total serum IgE (OR 2.14 [95%CI 1.14-4.00]; P 0.017). Analysis of 
additional phenotypes revealed significant association with allergic rhinitis in the context of 
eczema (OR 4.04 [95%CI 2.11-7.72]; P 2.4x10-5), the early onset form of eczema (OR 
5.21 [95%CI 2.61-10.40]; P 2.8x10-6) and the more severe and persistent type of eczema 
as measured with the “Score of Atopic Dermatitis” (SCORAD) (OR 2.65 [95%CI 1.36-
5.17]; P 0.0043). Again, there was no association observed with the intrinsic form of 
eczema (chapter 2.2). 
III.  In order to investigate distribution and impact of FLG variants in the general 
population and to uncover their role in other atopic phenotypes like asthma and rhinitis the 
five most prevalent variants R501X, 2282del4, R2447X, S3247X and 3702delG were 
studied in a large cross-sectional study population, consisting of 3099 children recruited in 
Munich and Dresden as part of the ISAAC II study. Carrier frequencies on population level 
were 4.6% for 2282del4, 1.9% for R501X, 0.7% for R2447X and 0.2% for S3247X yielding 
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a combined carrier frequency of 7.4%. No carriers of the 3702delG mutation could be 
identified. 
As expected, the analyzed variants (combined genotype) were strongly overrepresented 
in eczema affected individuals and increased disease risk more than threefold (OR 3.12 
[95%CI 2.33-4.17]; P 2.5x10-14). Accordingly, FLG alleles conferred an increased risk for 
sensitization (OR 1.61 [95%CI 1.20-2.17], P 0.0017). Penetrance of FLG null alleles 
reached 38.5%, indicating the proportion of individuals bearing at least one mutant FLG 
allele concurrently presenting the clinical disease phenotype. The proportion of eczema 
affected individuals in the general population explained by the presence of one or more 
FLG risk variants, commonly described as Population Attributable Risk, was 13.5%. 
Additionally, significant association with allergic rhinitis independently from eczema status 
was observed (OR 2.64 [95%CI 1.76-4.00]; P 2.5x10-6), whereas association with asthma 
appeared only to be significant in combination with eczema (OR 3.49 [95%CI 2.00-6.08]; 
P 1.0x10-5). Of note, histological analysis of the nasal epithelium showed strong 
expression of FLG in the vestibular lining, but lack of expression in the transitional 
epithelium and in the respiratory mucosa (chapter 2.3). 
IV. The FLG gene and its polymorphisms represent one of the most widely replicated risk 
factor in the area of complex diseases. However, results of the numerous studies differ 
largely concerning effect size, and there exists a conflict of statements regarding FLG null 
mutations and their possible influence on asthma. The conducted meta-analysis 
represents the most comprehensive evaluation of the effect of FLG loss-of-function 
mutations and the first meta-analysis on asthma so far. 
A total of 24 studies on FLG mutations and eczema comprising nearly 5,800 cases, > 
26,000 controls and nearly 2,000 families were included in this analysis. For asthma, there 
were 17 studies with > 3,000 cases, > 17,000 controls and > 1,500 affected family 
offspring available. In the combined analysis of the two most common variants R501X and 
2282del4 in all family and case-control studies a more than threefold increased risk for 
eczema was confirmed (OR 3.12 [95%CI 2.57-3.79]). In the case of asthma, it seems to 
be indeed exclusively the combined asthma + eczema phenotype (OR 3.29, [95%CI 2.84-
3.82]) that is genetically determined by FLG null alleles, but not asthma without eczema. 
An evaluation of all included studies concerning study design (e.g. population size, 
determination of disease status etc.) revealed strongest association for affected 
individuals with a dermatologist’s diagnose and the more severe form of eczema (chapter 
2.4). 
V.  In the first and to date only GWAS on eczema with more than 307000 SNP markers 
in >3500 cases, >4900 controls and 270 nuclear families (parent-child trios), a so far 
unknown susceptibility locus on chromosome 11q13.5 could be identified. The minor allele 
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A of rs7927894 showed a highly significant association (ORcombined 1.22 [95%CI 1.15-
1.30]; Pcombined 7.6x10-10) with the disease in all four independent study populations. The 
associated SNP rs7927894 is located in an intergenic region on chromosome 11, 38kb 
downstream of the gene C11orf30 encoding the EMSY protein and 68kb upstream of 
LRRC32 encoding the GARP protein (glycoprotein A repetitions predominant), two 
pathophysiologically very interesting and hitherto disregarded candidates for eczema. 
There was no evidence for any regulatory influence of rs7927894 on mRNA expression of 
both genes in a public available dataset of a GWAS for global mRNA expression in 
lymphoblastoid cell lines from asthmatic children (Dixon, Liang et al. 2007) and the causal 
variant(s) are still to be determined. 
The observation of an additional association signal located in the EDC around the 
hornerin (HRNR) gene (lead SNP rs877776, Pcombined 3.5x10-5) after exclusion of 
individuals carrying any of the five most prevalent FLG mutations points strongly towards 
a second risk factor in this intriguing region apart from FLG and represents a novel 
susceptibility locus for eczema in the EDC (chapter 2.5). 
VI. Analysis of human serum IgE concentrations in a genome-wide scan consisting of 
more than 353000 SNP markers and more than 11.000 individuals from 4 independent 
population based cohorts revealed that variants in the α chain of the high affinity receptor 
for IgE strongly impact basal IgE regulation. Two polymorphisms (rs2251746 and 
rs2427837) in this gene were strongly associated across all cohorts with combined P-
values of 1.85x10-20 and 7.78x10-19, respectively. The estimated effect of SNP rs2427837 
can be translated in a decrease of approximately 19.1% of IgE level in heterozygous 
carriers and 34.6% for homozygous carriers of the rare A allele. Additional functional 
studies showed a significant decrease of FCER1A cell surface expression on basophils 
for the AA genotype of rs2427837. This observation is in line with a previous Japanese 
study, which had demonstrated that polymorphism rs2251746, which is in complete LD 
with rs2427837, alters expression of FCER1A (Hasegawa, Nishiyama et al. 2003). A post-
hoc analysis of these two SNPs for different atopic traits demonstrated additional 
associations with allergic sensitization (P 7.78x10-4 and 1.95x10-3 for rs2251746 and 
rs2427837, respectively). Supplemental exon sequencing of FCER1A in 48 male and 48 
female individuals equally selected from the extremes of serum IgE distribution in KORA 
S4 did not reveal any new prevalent mutation in this gene. 
Apart from FCER1A, several variants located within the IL13-RAD50 locus with consistent 
effect estimates and combined P-values of 6.28x10-7 to 4.46x10-8 showed associations 
with IgE levels. The most significant SNP rs2706347 was associated with an estimated 
increase of 15.4% and 33.1% of total IgE for heterozygous/homozygous carriers of the 
minor allele, respectively. These four associated polymorphisms in the RAD50 gene were 
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additionally observed to be risk factors for eczema and asthma in subsequent analyses in 
a cohort of 562 German eczema families and an asthma case-control study including 638 
asthmatics and the same number of controls from UK (chapter 2.6). 
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3 Discussion 
The skin represents a highly effective physical and biomechanical as well as immunological 
barrier. The immunological skin barrier relies on innate immune receptors and components of 
the adaptive immune system, whereas the physical barrier is mainly provided by the stratum 
corneum, a dense layer of protein-rich cells within an intercellular matrix of unpolar lipids. 
Efficient function of the skin barrier critically depends on proper formation and composition of 
the SC and it is increasingly recognized that deficiency of the epidermal barrier might be 
largely due to genetic defects in SC proteins or lipids. With the discovery of loss-of-function 
mutations in the key SC protein filaggrin as causative for ichthyosis vulgaris and strong risk 
factors for eczema, first evidence for the involvement of defective structural epidermal 
proteins due to genetic alterations in skin barrier disruption has been established. 
 
Filaggrin: Evidence for a crucial role of skin barrier dysfunction in eczema 
Within the scope of this thesis, three independent association studies on common FLG 
mutations were carried out to validate and further dissect the role of this gene in eczema 
pathogenesis. By examining a collection of 476 German parent-affected offspring trios the 
first independent confirmation of the association between common FLG loss-of-function 
mutations (R501X and 2282del4) and eczema could be provided. In addition, it could be 
shown that these variants are also associated with the presence of palmar hyperlinearity, a 
characteristic feature for IV called “ichthyosis-hand”, which is also considered a strong sign 
for atopic constitution and often observed in eczema patients (Przybilla, Ring et al. 1991). In 
a subsequent case-control and a population-based approach FLG null mutations were 
consistently associated with total and specific serum IgE levels. Accordingly, in all three 
studies a particularly strong association was observed for the atopic subtype of the disease 
(eczema with allergic sensitization). It was demonstrated that FLG variants also strongly 
predispose to a subtype of asthma that occurs in the context of eczema. Moreover, FLG 
deficiency revealed to be a risk factor for the early-onset and severe and persistent subtypes 
of eczema. In the large-scale population-based study in German children the mutant FLG 
alleles showed an incomplete penetrance of 38%. The population attributable risk reached 
13.5%, which means that more than 13% of eczema cases in the population can be 
attributed to FLG deficiency. 
The comprehensive summary of these results as well as those of numerous other studies in 
the performed meta-analysis provides strong evidence for a genetically determined FLG 
deficiency as major risk factor for the development of eczema. Careful evaluation of the risk 
estimates conferred by mutant FLG alleles in the different studies, which partially showed 
large divergences, revealed a more than threefold increase in eczema susceptibility and a 
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more than threefold elevated risk for the compound phenotype asthma + eczema. Taken 
together, these observations provide evidence for the hypothesis that the impaired 
aggregation of filaments in the skin caused by lack of filaggrin leads to an impaired barrier, 
which might facilitate the penetrance of environmental agents such as allergens. This 
consequently might promote inflammation and allergic sensitization, and the development of 
the atopic form of eczema (Fig. 7), eventually followed by asthma and rhinitis. Filaggrin is not 
expressed in the human bronchial mucosa (Ying, Meng et al. 2006). However, the disruption 
of the epidermal barrier due to an inherited filaggrin deficiency might allow the entry of 
allergens and initiation of a systemic TH2 response affecting organs like the lung (Hudson 
2006). The hypothesis that allergic sensitization might happen in the skin is supported by the 
observation that an exposure to topical emollients containing peanut proteins can lead to 
peanut allergy in children (Lack, Fox et al. 2003), and that epicutaneous exposure to peanut 
allergen causes allergic sensitization in mice (Strid and Strobel 2005). Hence, skin-mediated 
sensitization seems to depend critically on the integrity of the skin barrier and even includes 
possible sensitization against food allergens. 
 
 
Figure 7: Hypothesis concerning the natural history of eczema. Environmental factors and a 
genetically determined epidermal barrier dysfunction cause non-atopic eczema as the first 
manifestation of the disease. Subsequent IgE-mediated sensitization due to a genetically determined 
immune response dysfunction occurs, additionally triggered by S. aureus infections. Finally, patients 
may become sensitized to self-proteins because of scratching and the release of structural proteins 
from damaged tissue. From (Bieber 2008) 
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This work strongly supports the change in concepts for eczema pathogenesis indicating that 
a genetically derived defect in the epidermal barrier plays a pivotal role in the development of 
this disease, probably followed by IgE-dependent sensitization and the subsequent onset of 
respiratory diseases (Hudson 2006). 
However, around 60% of individuals affected by eczema do not carry any of the known 
mutations in the FLG gene, but there are first hints indicating that FLG expression in the skin 
might be modified by additional genetic and environmental factors. Recently, a decreased 
expression of filaggrin in acute skin lesions of eczema patients without FLG mutations was 
observed and attributed to the TH2 cytokine milieu, since it could be shown that the 
expression of FLG is downregulated by IL-4 and IL-13 (Howell, Kim et al. 2007). Thus, TH2 
cytokines not only represent critical mediators of the allergic immune response, but 
additionally seem to contribute to the skin barrier disruption in eczema patients. Another 
possible explanation for reduced levels of the FLG protein in the epidermis of eczema 
patients displaying the FLG wildtype might be an alteration in profilaggrin processing. FLG is 
primarily expressed and stored as a non-functional precursor in the stratum granulosum, and 
accurate activation by posttranslational modification is of high importance. The protease 
SCCE is supposed to be responsible for proteolytic cleavage of profilaggrin (Resing, Thulin 
et al. 1995) and seems to be regulated by LEKTI, a serine protease inhibitor. A genetic 
association study performed by our group (Weidinger, Baurecht et al. 2008) on KLK7 
(kallikrein-related peptidase 7), the gene encoding SCCE, as well as SPINK5, which encodes 
LEKTI, did not confirm the association between KLK7 and eczema, as reported in previous 
studies (Vasilopoulos, Cork et al. 2004) but revealed a polymorphism in SPINK5 to confer 
increased risk of eczema when maternally inherited. Analysis of a possible interaction 
between FLG, SPINK5 and KLK7 in the same study did not show any significant epistatic 
effects. Therefore, besides a direct genetic influence on expression due to mutations in the 
FLG gene itself, filaggrin insufficiency might be indirectly caused by acquired and/or inherited 
factors influencing its expression and/or posttranslational processing. 
A variety of studies points towards a genetically determined FLG deficiency as risk factor for 
other epidermal disorders. Apart from (atopic) eczema, our study in a population-based 
cohort of German adults revealed an additional association of FLG mutations with allergic 
contact sensitization against certain allergens as well as with allergic contact dermatitis 
(Novak, Baurecht et al. 2007). These observations are in line with studies provided by other 
groups, which reported associations with chronic-irritant hand-eczema and severe courses of 
alopecia areata and X-chromosomal ichthyosis (de Jongh, Khrenova et al. 2008), whereas 
FLG variants seem to be no risk factor for psoriasis vulgaris. Although a reduced expression 
of FLG has been observed in psoriatic lesions (Watanabe, Wagatsuma et al. 1991; 
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Huffmeier, Traupe et al. 2007), an association between FLG variants and psoriasis could not 
be demonstrated (Weichenthal, Ruether et al. 2007; Zhao, Terron-Kwiatkowski et al. 2007).  
The functional consequences and exact phenotypic characteristics caused by FLG mutations 
are not completely understood and the hypothesis of a "dry or defective barrier" in FLG-
mutation carriers remains to be proven (Irvine 2007). There still remains a need to dissect 
the possible impact of FLG mutations in other allergic diseases, such as asthma, rhinitis, 
sensitization and allergy to food and aeroallergens, and a variety of other diseases related to 
skin barrier disruption like psoriasis. 
Additional studies in carefully phenotyped, large scale and cross sectional longitudinal study 
populations are necessary to generate a clearer picture of mutant FLG and its influences on 
allergic diseases, certain subtypes of allergic phenotypes or secondary traits like serum IgE 
levels. Another helpful measure for detection of further genetic factors would be the 
subdivision of eczema cases in FLG-associated and FLG-independent disease, which might 
additionally facilitate delineation of environmental modifiers. 
An alternative approach to gain more insights into particular effects and phenotypic 
consequences of FLG deficiency might be the use of animal models e.g. a mouse-model, 
which provides the possibility of analysing various generations due to short life span and fast 
reproduction of these animals. Breeding of isogenic strains reduces the genetic 
heterogeneity between subjects, and controlled test settings allow examinations of gene-
environment interactions, e.g. reaction to allergen exposure. To date no feasible animal 
model exists that covers all the different aspects of eczema. Only the flaky tail (ft) mouse 
seems to hold the possibility to serve as comprehensive model for eczema pathogenesis and 
the role of FLG. However, the eczema-related phenotype characterized by inflammatory 
infiltrates in the epidermis and allergen-specific antibodies in this model only occurs in 
homozygous individuals, but lung inflammation or airway hyperresponsiveness could not be 
detected in percutaneously sensitized ft/ft mice (Fallon, Sasaki et al. 2009). These 
observations are contrary to data retrieved from human populations where heterozygosity of 
FLG mutations is sufficient to increase the risk for eczema and eczema-associated asthma. ft 
mice additionally fitted with deficiencies in IgE synthesis or other important TH2 promoting 
molecules will help to dissect the role of immune response, whereas exposition of ft mice to 
environmental factors might throw light on exogenous influences and their interaction with 
FLG deficiency. 
Taken together, FLG and its different null mutations appear to be the only strong and 
consistent eczema risk factor across different populations and in multiple large independent 
studies and their discovery represents a milestone in the area of atopic disease research. 
The assessment of phenotypic effects of FLG deficiency represents the first step towards the 
understanding of an important disease mechanism in the development of eczema, allergic 
Discussion  77 
rhinitis and asthma in the context of eczema. Although the functional consequences of FLG 
deficiency are still not fully understood, the recent findings on this gene already led to a 
change in the concept of eczema aetiology. The identification of several loss-of-function 
mutations in this gene opens up the possibility of reclassification of atopic diseases. The 
frequency of FLG variants in patients with eczema, which adds up to 40%, might be 
considered for a novel molecular eczema classification, based on underlying genetic defects 
rather than on clinical symptoms. A next step may be the development of methods for the 
restoration of epidermal skin barrier by means of superficially applicable crèmes and 
emollients containing substitutes for natural moisturizing substances (NMS), if not even for 
the filaggrin peptides itself. Reconstitution of FLG function could be achieved by the use of 
substances, which allow a read-through of DNA-polymerases over the disease causing null 
mutations, thereby clearing the lack of filaggrin and restoring functional skin barrier without 
any restriction. With the development of screening method using FLG mutations or deficiency 
as early biomarker, infants under high risk could be determined and measures for avoiding 
contact with allergens could be taken. With one or more of these actions the key event of 
sensitisation, probably leading to the subsequent development and progression of atopic 
disease like eczema or asthma may be prevented in childhood. Early disease management 
could improve the outcome and quality of life of patients with eczema. 
 
Genome-wide association study on eczema: identification of a novel susceptibility 
locus 
GWAS are hypothesis-free approaches and very useful tools in the identification of disease-
associated genes, especially without prior implication in pathogenic concepts. Likewise, the 
GWA study included in this thesis revealed a yet uncharacterized locus to be significantly 
associated with eczema. The study design of two different German discovery sets used in 
this approach consisted of a case-control and a family-based study population in order to 
exclude possible population stratification. The case-control set was additionally tested for 
possible population stratification by principal component analysis with Eigenstrat (Price, 
Patterson et al. 2006), which did not show any evidence for genetic stratification. Variants 
with the same risk allele consistently associated with eczema in both sets with p<0.005 in 
one population and p<0.05 in the other population were selected for replication in an 
independent and large cohort of German ancestry. Markers showing significant association 
in this replication cohort after Bonferroni correction were additionally tested in a second large 
replication set of European cases and controls. The study revealed an interesting novel 
susceptibility locus on chromosome 11q13.5, a second association signal independently from 
FLG on chromosome 1q21.3 within the EDC, as well as a number of nominally associated 
variants within or nearby plausible candidate genes. The latter six loci did not reach the 
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significance threshold in the first replication set after correction for multiple testing but 
included promising candidates like HRH4 (histamine receptor H4), LY86 (lymphocyte antigen 
86) and EOMES (eomesodermin). All these genes are known to be involved in 
immunological pathways like the differentiation of TH2 cells, mast cells, and eosinophils 
(HRH4) (Thurmond, Gelfand et al. 2008), Toll-like receptor mediated response to bacterial 
infections (LY86 or MD-1) (Nagai, Shimazu et al. 2002) and CD8+ T-cell function (EOMES) 
(Pearce, Mullen et al. 2003). As the calculated power for the detection of risk variants 
conferring a relative risk of 1.5 with a minor allele frequency of 20% is only about 12% for the 
performed analysis, it is very probable that additional low risk variants were missed due to 
false negative results. Additional genome-wide association or candidate gene approaches 
providing bigger sample sizes will be needed for follow-up and positive confirmation 
concerning these loci. 
The gene or gene product affected by the rs7927894 risk allele on chromosome 11 still 
remains to be identified and functionally characterized; the SNP rs7927894 is located in an 
intergenic region 38 kb downstream of C11orf30 and 68 kb upstream of LRRC32. C11orf30 
codes for the EMSY protein, which has been implicated in DNA repair, chromatin regulation 
and transcriptional regulation. It has been reported to bind to the breast cancer susceptibility 
protein BRCA2 and to be involved in epithelial-derived cancer of the breast and the ovaries 
(Hughes-Davies, Huntsman et al. 2003), and might play a role in epithelial differentiation. 
GARP, which is encoded by the second nearby gene LRRC32, has been shown to be a cell 
surface molecule expressed on regulatory T-cells, which binds TGF-beta (transforming 
growth factor beta) (Wang, Wan et al. 2008). Therefore it also represents a plausible 
candidate for eczema susceptibility, given the important role of T-cell-mediated inflammation. 
RNA-expression profiling in different tissues showed ubiquitous expression of both genes, 
even in eczema relevant tissues like the skin. Although the associated variant is located in an 
LD block, which extends into C11orf30, it cannot reveal the associated gene, as correlated 
variants are located at both sides of the SNP. Moreover, rs7927894 or more likely a 
causative variant in LD with this SNP may be located in a non-coding regulatory sequence 
with effects on expression of LRRC32 of even more distant genes others than C11orf30 and 
LRRC32. Disruption of non-coding long-range regulatory elements, in many cases acting 
over distances spanning various intermediate genes, is an emerging disease mechanism 
(Kleinjan and van Heyningen 2005).  
Interestingly, association of the rs7927894 allele A has recently also been shown in a GWAS 
for Crohn’s disease (CD) (Barrett, Hansoul et al. 2008), another complex disorder, which is 
characterized by a chronic and recurrent inflammation of the gastrointestinal tract. CD and 
eczema are known to show some pathophysiological similarities like inflammation and 
impairment of the epithelial barrier and restrictions of the innate immune system (Schreiber, 
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Rosenstiel et al. 2005). SNP rs7927894 seems to convey susceptibility to both diseases, 
which might contribute to the high incidence of eczema observed in CD patients (Pugh, 
Rhodes et al. 1979). Thus, genetic factors beyond skin-specific physical barrier genes may 
have an effect on susceptibility to epithelial inflammation with similar function in different 
inflammatory diseases affecting both the skin and the gastrointestinal tract. Although highly 
speculative, it is tempting to suggest that the 11q13.5 variant may also contribute to a TH1-
dominant immune profile as seen in CD as well as in chronic atopic eczema lesions rather 
than to the TH2-dominant lesions of acute atopic eczema.  
In the meantime, association of rs7927894 [A] has been replicated in an independent Irish 
study, which confirmed allele frequency of the risk variant and showed a similar OR 
(O'Regan, Campbell et al. 2010). 
The results obtained from the GWAS require further investigations on the functional 
consequences on the biomolecular level caused by rs7927894 or any functional variant in LD 
with this SNP. LD structure retrieved from HapMap Phase 1 & 2-full data set 
(http://hapmap.ncbi.nlm.nih.gov/index.html.en) shows correlation of rs7927894 with a variety 
of variants on both sides of the SNP. Hence LD data alone does not reveal, which of the two 
genes is of prior interest for functional analysis. To give a short outline, polymorphisms in LD 
(D’>0.8) in a 750kb surrounding region of rs7927894 are located mostly in the intergenic 
region between C11orf30 and LRRC32. Several SNPs can be found in the 3’ region of 
LRRC32 or in C11orf30 itself, and some correlated variants are located in the guanylat 
cyclase 2E pseudogene (GUCY2E) downstream of LRRC32 or in the intergenic region 
between C11orf30 and the upstream protein kinase encoding gene PRKRIR (protein-kinase, 
interferon-inducible double stranded RNA dependent inhibitor, repressor of (P58 repressor)). 
In order to draw first conclusions on a possible functional involvement of rs7927894 
neighbouring genes, potential differences in mRNA expression for the two candidate genes 
C11orf30 and LRRC32 in the large and well-characterised KORA research platform and 
genome-wide expression data will be analysed. 
Considering the possible regulatory role of the SNP containing intergenic region, an intensely 
public database research for the rs7927894 surrounding region regarding conservation, 
regulatory potential and predicted enhancer regions using the University of California Santa 
Cruz (UCSC) genome browser (http://www.genome.ucsc.edu/), Vista Genome browser 
(http://pipeline.lbl.gov/cgi-bin/gateway2), and Vista Enhancer browser 
(http://enhancer.lbl.gov/) was conducted. A conserved sequence with high regulatory 
potential and different conserved transcription factor binding sites in a 1kb region 
(Chr11:75,977,000-75,978,000) upstream of rs7927894 was observed. Several SNPs are 
located in this region and might display LD with the original SNP associated in the GWAS. 
Unfortunately LD calculation is not possible, because none of these polymorphisms has been 
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genotyped in the course of the Hap Map project. Therefore a reasonable experiment would 
be an enhancer analysis by transfection of enhancer minimal promoter constructs into 
standard cell lines and measurement of enhancer activity by luciferase reporter gene assay. 
Identification of possible DNA interacting proteins could be examined via electrophoretic 
mobility shift assays (EMSAs), DNA-affinity purification and mass-spectrometry. 
Bioinformatic results obtained from the before mentioned preliminary public database 
research additionally revealed another very interesting region. A polymorphism (rs1044265) 
located in the 3’ untranslated region (UTR) of C11orf30 near several microRNA regulatory 
sites and within a MEF-2A (myocyte-specific enhancer factor 2A) binding site seems to be in 
strong LD (D’=0.83) with rs7927894. MicroRNAs are supposed to regulate ~30% of all 
human genes via binding to 3’UTR mRNA sequences, and several polymorphisms in these 
regions have been shown to exert effect on gene expression (Lau, Lim et al. 2001; Lee and 
Ambros 2001; Sevignani, Calin et al. 2006; Yanaihara, Caplen et al. 2006). Hence, 
rs1044265 may interfere with miRNA function leading to differential gene expression of 
C11orf30. To test this hypothesis miRNA regulation assays and mRNA stability assays are 
planned. 
The second significant association signal identified in this GWAS belongs to SNP rs877776 
located within the hornerin gene (HRNR) in the EDC on chromosome 1q21.3. The risk allele 
could only be detected after stratification for FLG lof-mutations, i.e. statistical analysis after 
exclusion of individuals carrying any of the known FLG variants. This observation reflects the 
basic need for determination of -at least- the two most common FLG mutations R501X and 
2282del4 in study populations used in future GWAS on eczema or in candidate gene 
association studies including loci within the EDC. The possibility of an associated SNP being 
only in LD with any of the FLG variants require stratification in order to detect true 
association apart from FLG. Before stratification for mutant FLG carriers the performed 
GWAS showed a significant association signal of SNP rs6661961 (P ≤ 3x10-3), which is 
located in the EDC 156kb downstream of FLG. Association with this variant was observed in 
both discovery populations and replicated in a follow-up study sample. Subsequent LD 
analysis revealed high LD between this marker and the FLG mutations, and stratification for 
FLG mutation carriers abolished the observed association (P > 0.5). However, these results 
serve as a positive control for this association study, as they reconfirm association with FLG 
and thereby robustness of the study. Stratification is all the more important as the EDC still 
seems to harbour further genes involved in eczema development. A variety of candidates 
with important function in the development of the epidermal barrier are located in this region, 
each of which might cause defects in the formation of the cornified envelope. One or more 
independent risk genes might exist within the EDC that similar to FLG but independently of it 
cause skin barrier dysfunction with the effect of facilitated allergen penetration and systemic 
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allergic reactions. Risk alleles in FLG-unstratified eczema populations might be 
underrepresented due to 20-40% of eczema patients carrying one or more FLG mutation. 
False negative results could occur because of dilution of novel risk gene effects by FLG, 
whereas the statistical power to detect a true association with further independent risk gene 
in the EDC increases after exclusion of patients with eczema caused by FLG variants. 
However, it has to be mentioned that SNP rs877776 could not be replicated within the same 
Irish study, which successfully reproduced the observed association for rs7927894 
(O'Regan, Campbell et al. 2010). Although the examined eczema cases belong to the 
discovery cohort for FLG mutations and are very well characterized for its rare and prevalent 
loss-of-function variants (Palmer, Irvine et al. 2006) stratification for FLG variants did not 
reveal any association within the EDC. It might be speculated that the Irish study including 
500 cases and 1000 controls did not have enough power to detect effects of the HRNR 
variant due to a relatively low allele frequency of ~16% and a small effect size (OR 1.20). As 
FLG mutations are known to be population specific, rs877776 might also be in LD with a yet 
unidentified FLG variant unique to continental Europeans, which does not appear in the Irish 
study cohort used for replication analysis. 
The performed GWAS suggests that FLG might not be the only risk gene within the EDC 
responsible for linkage and association signals. Additionally, a variety of different 
inflammatory diseases has been linked to the EDC, like psoriasis, asthma, systemic lupus 
erythematosus (SLE) and rheumatoid arthritis (Willis-Owen, Morar et al. 2007). For most of 
the latter diseases, no susceptibility gene has been identified within this region so far. 
However, a recent GWAS on psoriasis assumed the presence of a susceptibility gene in the 
EDC (Liu, Helms et al. 2008), the PSORS4 locus on 1q21 has been repeatedly confirmed in 
independent patient cohorts (Capon, Semprini et al. 2001; Giardina, Sinibaldi et al. 2006), 
and a copy number variation within the late cornified envelope (LCE) genes has been shown 
to be associated with increased risk for psoriasis (de Cid, Riveira-Munoz et al. 2009; 
Huffmeier, Bergboer et al. 2010). Hence, the EDC still represents a very promising region in 
search of further risk genes, not only for eczema, but although for other inflammatory barrier 
diseases, and its comprehensive analysis is of high importance. 
Therefore we have started an in-depth analysis of genetic variants within the EDC in order to 
discover novel mutations, confirm annotated SNPs and detect rare variants and unravel their 
role in eczema and psoriasis. The spectrum of polymorphisms in the EDC including the 
region between the S100A10 and S100A1 (S100 calcium binding protein A) genes from 
position 148700000 to 150500000 on chromosome 1q21.3 will be explored by massive 
parallel sequencing with next generation sequencing (Illumina Genome Analyzer or Solexa). 
SNPs and novel mutations in 61 genes of the EDC will be systematically screened by 
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resequencing this 2megabases (Mb) chromosomal region (Figure 8) in at least 100 
eczema/psoriasis cases and 100 healthy controls. 
 
Figure 8: Schematic physical map of human chromosome 1q21.3 representing the different 
gene families. The EDC includes a region of 1.62 Mb on chromosome 1q21.3 and constitutes a 
dense cluster of approximately 50 genes involved in the final differentiation of the epidermis. These 
genes can be subdivided into functionally, structurally and evolutionary related families: the small 
proline rich proteins (SPRs), involucrin (IVL) and loricrin (LOR), the S100A family, the late cornified 
envelope proteins (LCEs) and a few single copy genes of the “fused type” family including filaggrin 
(FLG), filaggrin2 (FLG2), hornerin (HRNR), cornulin (CRNN), repetin (RPTN) and trichohyalin (TCHH). 
The fused type family is characterised by a large repeat domain of several protein motifs arranged in 
tandem (reviewed in ((Rodriguez, Illig et al. 2008)). 
Subsequently to in depth sequencing and the discovery of novel variants, an association 
analysis of selected polymorphisms in sufficiently powered case-control-cohorts for eczema 
and psoriasis will be necessary, and associated variants in putative disease genes will have 
to be confirmed in additional and independent study populations. Moreover, validated risk 
genes will be functionally evaluated by in vitro-analysis of tissue-specific and cell-type 
specific expression patterns during differentiation using real time-PCR (RT- PCR) and in situ 
hybridization. 
Limitations of this method are not only its time- and cost expenditure –although next 
generation sequencing methods already provide a much better time- and cost effectiveness 
compared to traditional sequencing methods - which restrict the projected approach to a 
relatively small set of samples to be sequenced. But it’s also hampered by the already 
mentioned structural nature of a variety of genes like FLG and the fused type family in 
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general, with it’s commonly highly repetitive genomic sequence, and the bioinformatic 
challenge to handle and comprehensively analyze the huge amount of generated data. 
Likewise to the fast developing field of new GWAS techniques, the term “next-generation” 
sequencing already seems to be antiquated, and the new slogan of “Third generation” 
sequencing has been coined. New methods promise to increase speed of data generation 
while costs are concurrently decreasing (Check Hayden 2009; Eid, Fehr et al. 2009). 
However, still we have not reached the 1000$ genome widely thought to be necessary for 
broad medical use in diagnosis and individualized medical treatment (Mardis 2006). 
The strong impact of FLG mutations, which have a rather low individual frequency, on 
eczema and allergic rhinitis challenges the popular hypothesis “common disease-common 
variant”, which proposes that the genetic variations underlying common disorders such as 
allergic diseases must be alleles, which are themselves very common in the general 
population (Lander 1996; Chakravarti 1999). Up to now it has provided the scientific 
paradigm for genome-wide association studies conducted on common diseases (Wang, 
Barratt et al. 2005). As coverage of all genomic variants within a genome-wide association 
approach is still not possible, SNP selection for these arrays is generally based on an even 
physical distribution of markers throughout the genome with regard to genomic LD 
architecture in order to capture redundant information about as many SNPs as possible, or 
concentrates on coding regions and recombinant hotspots. However, this strategy does not 
necessarily hold for all genetic factors involved in polygenic diseases (Pritchard 2001; 
Pritchard and Cox 2002), and analysis of FLG loss-of-function mutations highlights its 
limitations. Rare variants with minor allele frequencies of < 10% like the FLG polymorphisms, 
which only reach a frequency of ~10% when combined, are generally not included in 
purchasable standardized genome-wide chip applications and might therefore slip through 
scientists fingers.  
GWA approaches offer the big advantage of hypothesis free search for disease genes that is 
not hampered by certain disease concepts and restricted to selected candidate genes. 
GWAS have already proofed to be useful and reliable tools for the identification of new and 
robust susceptibility loci for different complex diseases (Frazer, Murray et al. 2009). For e.g. 
Crohn’s disease, genome-wide approaches already revealed an impressive number of new 
risk genes, which, however, only explained a small proportion of the total variance in disease 
risk (Barrett, Hansoul et al. 2008). This unexpected case of “missing heritability” observed in 
genome-wide analyses already represents a dictum in the scientific community (Maher 
2008). Due to the fact that genome-wide arrays still do not cover variants with a minor allele 
frequency (MAF) < 10%, rare variants with stronger effects are missed. Many scientists 
strongly support the concept that few rare variants displaying relatively strong effects as well 
as numerous common variants with a rather low impact on the phenotype play crucial roles 
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in the aetiology of complex diseases (Maher 2008; Schork, Murray et al. 2009). Only a 
combination of both candidate gene association studies and GWAS will give a complete 
picture of the disease underlying mechanisms. However, as already mentioned, different 
sequencing projects like the 1000 genome project provide genome-wide platforms with a 
increasing number of new common and -most importantly- rare variants with minor allele 
frequencies below 10%. Genome-wide coverage of these SNP arrays will increase 
significantly during the next years, although whole genome sequencing in large cohorts 
seems to be the still unfeasible gold-standard for a real genome wide analysis in order to 
dissect the majority of genetic factors, which underlie complex diseases. 
 
GWAS on total IgE: insights into the genetic architecture of atopic disease risk 
In order to identify novel susceptibility genes influencing total IgE levels as a crucial outcome 
of allergic reactions, a GWAS in five independent, large-scale, and population-based 
German study samples was performed. In contrast to the often used case-control study 
design, the population-based approach allows estimation of genetic impact across the full 
range of IgE levels as observed in the common population, including individuals that are 
genetically predisposed but clinically unaffected. As none of the tested SNPs reached 
genome-wide significance (P<1.4x10-7) in the KORA S3/F3 discovery set, variants showing 
P-values of <10-4 and/or P<10-3 with at least one neighbouring SNP reaching the same P-
value were selected for genotyping in the first replication set (KORA S4). Two variants within 
the gene for the high affinity IgE receptor α chain (FCER1A) were shown to be significantly 
associated with total IgE, as well as four SNPs in the RAD50 gene, which is located within 
the TH2 cytokine-cluster on chromosome 5q31. All SNPs were subsequently validated in 
three additional children cohorts (LISA (Influences of life-style related factors on the immune 
system and the development of allergies in childhood), GINI (German Infant Nutritional 
Intervention Study), ISAAC). Furthermore, tagging SNPs covering the associated loci as well 
as functionally interesting literature SNPs were selected for finemapping. Association of IgE 
concentrations with a variant in the signal transducer and activator of transcription 6 gene 
(STAT6), a key regulatory element of the TH2 immune response, which has been shown to 
influence regulation of total serum IgE in previous studies (Schedel, Carr et al. 2004; 
Weidinger, Klopp et al. 2004), was reconfirmed. 
The two associated FCER1A polymorphism rs2251746 and rs2427837 were consistently 
associated with alterations in IgE levels across all study populations. The estimated effect of 
SNP rs2427837 can be translated in a decrease of approximately 19.1% of the IgE level in 
heterozygous carriers and 34.6% in homozygous carriers of the rare A allele. The most 
significant SNP in the second associated loci on chromosome 5q31 showed an estimated 
effect of 15.4% and 33.1% increase in total IgE levels for heterozygous and homozygous 
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carriers of the risk allele, respectively. Effect estimates for the STAT6 variant accounted for 
an increase of 16.9% for the rare heterozygous, and 36.6% for the rare homozygous 
genotype in total serum IgE concentrations. The variance in total IgE levels explained by the 
risk alleles of the three detected susceptibility regions accounts for about 1.9%. 
Up to date, only very few loci have been found to be consistently associated with serum IgE 
levels, like for example IL-13 and STAT6 (Ober and Hoffjan 2006; Vercelli 2008). Previous 
candidate gene studies focused exclusively on the β-subunit of the high affinity IgE receptor 
(FCER1B), which is known to play an essential role in the regulation of FCER1 cell surface 
expression and intracellular signalling (Kraft, Wessendorf et al. 1998; Donnadieu, Jouvin et 
al. 2000), reported association of variants within this gene and atopy-related traits, but 
conflicting results for IgE levels (Shirakawa, Li et al. 1994; Shirakawa, Mao et al. 1996; 
Ulbrecht, Eisenhut et al. 1997; Palmer, Rye et al. 1999; Hizawa, Yamaguchi et al. 2000; 
Hizawa, Yamaguchi et al. 2001; Traherne, Hill et al. 2003; Hoffjan, Ostrovnaja et al. 2004; 
Maier, Howson et al. 2006). In this GWAS no evidence for association of FCER1B with total 
IgE levels could be observed, which, however, might be due to low coverage of the FCER1B 
gene on the used Affymetrix 500K array chip. 
Instead, the first genome-wide screen on total IgE identified the α chain of the high affinity 
IgE receptor as a novel susceptibility locus. Additionally performed functional studies on the 
two SNPs that are located in the putative promoter region of FCER1A showed a significant 
decrease of FCER1A cell surface expression on basophils for the AA genotype of rs2427837 
in accordance to a previous Japanese study which demonstrated that polymorphism 
rs2251746, which is in complete LD with rs2427837, influences expression of FCER1A 
(Hasegawa, Nishiyama et al. 2003). Interestingly, only the α-subunit of the IgE receptor binds 
to the IgE-antigen complex, whereas the β and γ subunit lack physical contact. Further 
examinations revealed weak effects of both SNPs on allergic sensitization, whereas no 
association with eczema or asthma per se in independent case-control cohorts could be 
observed. In a recent study in two German birth cohorts rs2251746 was consistently 
associated with total serum IgE levels from birth up to the age of six years, exerting an allele-
dose effect. Again, no significant associations with asthma or eczema or interaction with 
different environmental exposures could be observed (Chen, Weidinger et al. 2009), 
indicating a role in basal IgE regulation. 
These observations add a new aspect to reports from different functional studies, which 
propose crucial regulation of cell surface expression of FCER1 through its ligand IgE. 
Correlation between the concentration of serum IgE and the amount of IgE bound to the 
basophils has been reported, and monomeric IgE has been shown to increase FCER1 
expression on the cell surface (Malveaux, Conroy et al. 1978; Furuichi, Rivera et al. 1985; 
Quarto, Kinet et al. 1985). It is supposed that IgE stabilizes the receptor complex on the cell 
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surface and restricts its internalization and degradation while maintaining basal synthesis, 
whereas there is no evidence for IgE-mediated increase in transcription or translation of 
FCER1. However, the exact regulatory pathway by which FCER1α expression might be 
linked to alterations in IgE serum levels remains unknown. 
Although the 5q31 region has already been linked to total IgE (Marsh, Neely et al. 1994) 
RAD50 has never been recognized as candidate prior to this GWAS. The gene encodes a 
DNA repair protein that is ubiquitously expressed, and therefore lacks any obvious biological 
connection to the analyzed trait. However, it contains a locus control region (LCR), which is 
supposed to regulate expression of the neighbouring TH2 cytokines (Loots, Locksley et al. 
2000). Hence, associated polymorphisms in RAD50 rather influence TH2 cytokine gene 
transcription than RAD50 regulation itself. The LCR is constituted by four RAD50 DNase I 
hypersensitive sites (RHS) in intron 21 (RHS4-6) and intron 24 (RHS7) (Fields, Lee et al. 
2004; Lee and Rao 2004; Lee, Spilianakis et al. 2005). RHS7 has been shown to be rapidly 
demethylated in murine cell lines of stimulated TH2-cells (Kim, Fields et al. 2007), an 
observation that might connect demethylating events in RHS7 with LCR activation under TH2 
conditions. Epigenetics is increasingly recognized as an important factor in complex diseases 
like eczema, and it provides a link between genetics and environment. Cells are enabled to 
change their behaviour in response to internal or external environmental influences. The 
best-studied epigenetic modification of DNA in mammals is methylation of cytosine in CpG 
dinucleotides (Bird 2002). We concurrently conduct a study analyzing the quantitative 
methylation status of CpGs within RAD50 which might reveal epigenetic regulatory pathways 
influencing cytokine expression and TH2 immune reaction in atopic individuals. Analysis is 
carried out using MassCLEAVE™ biochemistry and quantitative high-throughput mass 
spectrometry (Sequenom® MassARRAY® EpiTYPER system). Regions to be analyzed have 
been selected regarding presence of CpGs and CpG islands, conservation, regulatory 
potential and predicted enhancer regions using the UCSC genome browser 
(http://www.genome.ucsc.edu/), Vista Genome browser (http://pipeline.lbl.gov/cgi-
bin/gateway2), and Vista Enhancer browser (http://enhancer.lbl.gov/). To detect candidate 
RAD50 sites differentially methylated in allergic individuals, in a first step 48 RAD50 
amplicons covering the regions of high interest will be screened in peripheral blood DNA 
from eczema patients (n=20) and sex- and age-matched healthy controls (n=20) from our 
own disease collections. As methylation patterns are supposed to be highly tissue-specific, 
DNA from different cell types has been collected. The projected analysis includes peripheral 
blood samples, as well as DNA extracted from keratinocytes, T-cells and B-cells. In parallel, 
transcriptional expression of IL-4, Il-5 and Il-13 in peripheral blood leukocytes (PBL) will be 
assessed by RT-PCR to seek for correlations with methylation profiles. 
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Interestingly, further analysis of the RAD50 SNPs in independent case-control cohorts 
showed additional association with eczema and asthma, and in a very recently conducted 
independent GWAS the RAD50-IL-13 locus was strongly associated with asthma (Li, Howard 
et al. 2010), further supporting the role of variations within this locus for allergic diseases. 
Although RAD50 represents a new and biologically very interesting candidate due to its 
supposed regulatory function on TH2 cytokine expression, it has to be considered that 
several atopy-related susceptibility genes are located within the same cluster. IL-13 
represents one of this consistently associated genes (Ober and Hoffjan 2006; Vercelli 2008) 
and very recently, a functional variant in a DNase I hypersensitive site within the 
neighbouring IL-13 gene has been shown to be strongly associated with IgE levels (Kiesler, 
Shakya et al. 2009). Analysis of LD structure in the associated region revealed a LD block 
including the entire RAD50 gene and the IL-13 promoter region, and it is not possible to 
exclude the possibility of associated SNPs being in LD with functional variants within the IL-
13 gene. Hence, genetic variations within the RAD50-IL13 locus seem to be of importance 
for several atopy-related phenotypes, but final designation to one (ore more) specific 
susceptibility gene(s) is prevented by the complex LD-architecture characterizing this region, 
and functional studies are needed to dissect the underlying source of genetic association. 
Generally, elevated IgE levels are supposed to confer resistance against parasite infections, 
but they are strongly associated with allergic disorders in industrialized countries with less 
exposure to e.g. helminths. Recently it has been shown that an elevated IgE immune 
response is also involved in anti-tumoral defence (Gould, Mackay et al. 1999) and 
autoimmune diseases (Dimson, Giudice et al. 2003). Variability of IgE production has been 
shown to be largely influenced by genetic factors in pedigree and twin studies (Jacobsen, 
Herskind et al. 2001; Strachan, Wong et al. 2001). The decision for serum IgE levels as 
analyzed trait in this GWAS was based on its assumed role as endophenotype in atopic 
disorders like eczema. IgE largely fulfils the main criteria for such an endophenotype: It 
represents a precisely measurable and objective trait with sufficient heritability, which is 
feasibly linked to atopic eczema. An understanding of the genetic mechanisms regulating 
total serum IgE levels might also aid in the dissection of the genetic basis of atopic diseases. 
However, different independent GWAS on asthma and eczema only evidenced a small 
degree of overlap between identified susceptibility loci for atopic traits and total IgE, and 
disease-specific factors seem to be of high importance. Our knowledge about interrelation 
between the phenotypically very heterogeneous atopic diseases and the intermediate trait 
IgE is still very limited. Although the identified susceptibility genes seem to be important for 
the atopic state per se rather than a specific atopic disease, genetic research on 
endophenotypes will contribute to the clarification of allergic disease aetiology. 
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Figure 9: Schematic presentation of the interplay between barrier disruption and immune dysfunction 
in eczema aetiology highlighting genetically caused FLG deficiency and a mutant high affinity IgE 
receptor. 
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4 Concluding remarks 
It is widely recognized that atopic diseases such as eczema arise on the interplay of a strong 
genetic predisposition and environmental factors. New insights into the genetic architecture 
of eczema and atopy have considerably influenced our understanding of disease 
mechanism. Until recently common pathophysiological concepts for eczema focused on 
immunological mechanisms and postulated a central role of allergic sensitization and atopy. 
With the discovery of FLG mutations eczema and atopy are no longer considered as an 
exclusively immunological dysfunction, and the focus has shifted to the disruption of 
epithelial barrier integrity. FLG also challenges the “common disease-common variant” 
hypothesis and strengthens the idea of few rare variants conferring strong risk, which 
account not alone for the genetic aetiology of complex diseases but together with multiple 
common alleles conferring low risk. 
However, new risk genes described in initial association studies are often not reproducible 
and fail to replicate. To clarify the role of these possible susceptibility genes and in order to 
identify additional novel risk variants large-scale and well designed whole-genome 
association studies are needed. New technologies allowing the hypothesis-free search for 
new susceptibility loci already revealed various robustly associated risk genes for complex 
diseases, and technical limitations concerning whole genome coverage might be overcome 
within the next years. While awaiting the promised 1000$ genome which will enable 
researchers to analyze yet unknown rare variants, different consortia started meta-analysis 
approaches unifying the data from different large GWAS in order to uncover missing 
heritability in complex disease, as huge sample numbers provide the power to detect 
common genetic variants with modest or small effects. 
As not only technologies in the field of genomics advance very rapidly, but also new high-
throughput methods appear in proteomics and transcriptomics and in the relatively new fields 
of metabolomics and epigenomics, researchers of this different areas close ranks. The term 
of system biology tries to meet the complete picture in human disease research, and holds 
the promise of identification of new and easily applicable diagnostic tools as well as 
implementation of individualized therapies carefully adapted to the patient’s personal 
background. 
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